Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 2 of 68 PROTOCOL SYNOPSIS  
Protocol Number  
SGN35 -014 
Version  
Amendment 5 
Phase  
3 Product Name  
Brentuximab vedotin 
Sponsor  
Seattle Genetics, Inc.  
21823 30th Drive SE  
Bothell, WA 98021, USA  
Protocol Title  
A randomized, double -blind, placebo- controlled, phase 3 study of brentuximab vedotin and CHP (A +CHP) 
versus CHOP in the frontline treatment of patients with CD30 -positive mature T -cell lymphomas  
Study Objectives  
Primary:  
● To compare the progression -free survival (PFS) as determined by an independent review facility (IRF) 
between the 2 treatment arms  
Secondary:  
● To compare the PFS per IRF between the 2  treatment arms for patients with systemic anaplastic large cell 
lymphoma (sALCL)  
● To compare the remission rates  per IRF following the completion o f study treatment between the 
2 treatment arms  
● To compare overall survival (OS) between the 2 treatment ar ms 
● To evaluate the safety and tolerability of the 2 treatment arms  
Additional:  
● To evaluate medical resource utilization (MRU) and calculate utility values  
● To characterize the incidence of antitherapeutic antibodies (ATA) to brentuximab vedotin  
Study Population  
Inclusion Criteria  
1. Patients with newly  diagnosed, CD30- positive mature T -cell lymphomas per the Revised European -
American Lymphoma World Health Organization (WHO) 2008 classification by local assessment . Eligible 
histologies are limited to the f ollowing:  
● ALK -positive sALCL with an International Prognostic Index (IPI) score greater than or equal to 2  
● ALK -negative sALCL  
● Peripheral T -cell lymphoma – not otherwise specified (PTCL -NOS)  
● Angioimmunoblastic T -cell lymphoma (AITL)  
● Adult T -cell leukemia/lymphoma (ATLL; acute and lymphoma types onl y, must be positive for human 
T-cell leukemia virus 1)  
● Enteropathy -associated T -cell lymphoma (EATL)  
● Hepatosplenic T -cell lymphoma  
2. Fluorodeoxyglucose (FDG) -avid disease by PET and measurable disease of at least 1.5 cm by CT, as 
assessed by the site radiologist.  
3. Age greater than or equal to 18 years.  
4. An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.  
5. The following required baseline laboratory data:  
S t u dy  SGN35 -014   C l in i c a l  P ro t o co l     Am en dm en t  5 ;  12 -D e c em b e r -2018  
B r en t u x im ab  v edo t i n   S e a t t l e  G en e t i c s ,  In c .  -  C on f i d en t i a l   P ag e  3  o f  68  ● b i l i ru b i n  ≤1 .5X  u pp e r  l im i t  o f  n o rm a l  (ULN )  o r  ≤3X  ULN  fo r  p a t i en t s  w i t h  G i l b e r t ’ s  d i s e a s e  o r  
do cum en t ed  h ep a t i c  i nv o lv em en t  w i th  lym ph om a  
● a l an in e  am in o t r an s f e r a s e  (ALT )  an d  a s p a r t a t e  am i n o t r an s f e r a s e  (AST )  ≤ 3X  ULN  o r  ≤5X  ULN  f o r  
p a t i en t s  w i t h  do cum en t  h ep a t i c  i n v o lv em en t  w i t h  lym ph om a  
● s e rum  c r e a t i n in e  ≤2X  ULN  
● ab s o l u t e  n eu t roph i l  coun t  (ANC )  ≥1000 /µL  (u n l e s s  do cum en t ed  bon e  m a r row  i nv o l v em en t  w i th  
lym ph om a )  
● p l a t e l e t  cou n t  ≥50 ,000 /µL  (u n l e s s  do cum en t ed  bon e  m a r row  i n v o lv em en t  w i t h  lym ph om a )  
6 .  F em a l e s  o f  ch i l db e a r i n g  po t en t i a l  m u s t  h av e  a  n eg a t i v e  s e rum  o r  u r i n e  b e t a  hum an  ch o r i on i c  g on ado t roph i n  
(β -hCG )  p r egn an cy  t e s t  r e s u l t  w i th in  7  d ay s  p r i o r  t o  t h e  f i r s t  do s e  o f  s t u dy  t r e a tm en t  an d  mu s t  ag r e e  t o  u s e  
an  e f f e c t iv e  con t r a c ep t i on  m e th od  du r i n g  th e  s t u dy  an d  f o r  a t  l e a s t  6  m on th s  f o l l ow in g  th e  l a s t  do s e  o f  s tu dy  
d ru g .  F em a l e s  o f  n on -ch i l db e a r i n g  po t en t i a l  a r e  t h o s e  w h o  a r e  po s tm en op au s a l  g r e a t e r  th an  1  y e a r  o r  w h o  
h av e  h ad  a  b i l a t e r a l  t u b a l  l i g a t i on  o r  hy s t e r e c t om y .  
7 .  M a l e s  w h o  h av e  p a r t n e r s  o f  ch i l db e a r i ng  po t en t i a l  m u s t  ag r e e  t o  u s e  an  e f f e c t i v e  con t r a c ep t i v e  m e th od  
du r i ng  t h e  s t u dy  an d  f o r  6  m on t h s  f o l l ow i ng  th e  l a s t  do s e  o f  s t u dy  d rug .  
8 .  P a t i en t s  o r  t h e i r  l eg a l ly  au th o r i z ed  r ep r e s en t a t i v e  m u s t  p rov id e  w r i t t en  i n f o rm ed  con s en t .  
E x c lu s i on  C r i t e r i a  
1 .  H i s t o ry  o f  an o t h e r  p r im a ry  i nv a s i v e  c an c e r ,  h em a t o l og i c  m a l i g n an cy ,  o r  m y e l ody s p l a s t i c  sy n d rom e  th a t  h a s  
n o t  b e en  i n  r em i s s i on  f o r  a t  l e a s t  3  y e a r s .  
2 .  C u r r en t  d i agn o s i s  o f  any  o f  th e  f o l l ow i ng :  
● P r im a ry  cu t an eou s  CD30 -po s i t i v e  T -c e l l  lym ph op ro l i f e r a t i v e  d i s o rd e r s  an d  l ym ph om a s .  Cu t an eou s  
ALCL  w i th  ex t r a cu t an eou s  tum o r  s p r e ad  b ey on d  l o co r eg i on a l  lym ph  n od e s  i s  e l i g i b l e  (p r e v i ou s  s in g l e -
ag en t  t r e a tm en t  t o  add r e s s  cu t an eou s  an d  l o co r eg i on a l  d i s e a s e  i s  p e rm i s s i b l e ) .  
● My co s i s  fu ng o i d e s  (MF ) ,  i n c lu d i ng  t r an s f o rm ed  MF  
3 .  H i s t o ry  o f  p rog r e s s i v e  m u l t i f o c a l  l eu k o en c eph a l op a t hy  (PML ) .  
4 .  C e r eb r a l /m en i ng e a l  d i s e a s e  r e l a t ed  t o  t h e  u n d e r ly in g  m a l ig n an cy .  
5 .  P r i o r  t r e a tm en t  w i t h  b r en tux im ab  v edo t i n .  
6 .  B a s e l i n e  p e r i ph e r a l  n eu rop a t hy  ≥ G r ad e  2  ( p e r  t h e  NC I  CTCAE ,  V e r s i on  4 .03 )  o r  p a t i en t s  w i th  th e  
d em y e l in a t ing  f o rm  o f  Ch a r co t -M a r i e -Too t h  sy n d rom e .  
7 .  L e f t  v en t r i cu l a r  e j e c t i on  f r a c t ion  l e s s  th an  45%  o r  s ym p t om a t i c  c a rd i a c  d i s e a s e  ( i n c l u d ing  sym p t om a t i c  
v en t r i cu l a r  dy s fun c t i on ,  sym p tom a t i c  co ron a ry  a r t e ry  d i s e a s e ,  an d  sym p t om a t i c  a r rhy thm i a s ) ,  o r  m y o c a rd i a l  
i n f a r c t i on  w i th in  t h e  p a s t  6  m on t h s ,  o r  p r ev i ou s  t r e a tm en t  w i t h  com p l e t e  cum u l a t i v e  do s e s  o f  dox o ru b i c i n  o r  
o t h e r  an th r a cy c l in e s .  
8 .  Any  a c t i v e  G r ad e  3  (p e r  t h e  NC I  CTCAE ,  V e r s i on  4 .03 )  o r  h i gh e r  v i r a l ,  b a c t e r i a l ,  o r  f u ng a l  i n f e c t i o n  w i t h in  
2  w e ek s  p r i o r  t o  t h e  f i r s t  do s e  o f  s tu dy  t r e a tm en t ;  any  kn ow n  h um an  imm un od e f i c i en cy  v i ru s  (H IV )  
i n f e c t i on ,  h ep a t i t i s  B  su r f a c e  an t ig en -po s i t iv e  s t a t u s ,  o r  k n ow n  o r  s u s p e c t ed  a c t iv e  h ep a t i t i s  C  in f e c t i on .  
9 .  C u r r en t  t h e r apy  w i t h  o th e r  sy s t em i c  an t i - n eop l a s t i c  o r  i n v e s t i g a t i on a l  ag en t s .  
10 .  F em a l e s  w h o  a r e  p r eg n an t  o r  b r e a s t f e ed i ng .  
11 .  P a t i en t s  w i th  a  kn ow n  hy p e r s en s i t i v i ty  t o  any  ex c i p i en t  con t a i n ed  i n  th e  d ru g  f o rm u l a t i on .  
12 .  P a t i en t s  w i th  kn ow n  u r in a ry  ou t f l ow  ob s t ru c t i on .  
Numb e r  o f  P l ann ed  Pa t i en t s  
A pp rox im a t e ly  450  p a t i en t s  ( app rox im a t e ly  225  p a t i en t s  p e r  t r e a tm en t  a rm )  w i l l  b e  r an dom i z ed  i n  t h i s  s tu dy .  
S tud y  D e s i gn  
Th i s  i s  a  r an dom i z ed ,  dou b l e -b l i n d ,  p l a c ebo -con t ro l l ed ,  m u l t i c en t e r ,  ph a s e  3  c l in i c a l  t r i a l  d e s i gn ed  t o  ev a l u a t e  
t h e  e f f i c a cy  an d  s a f e ty  o f  in c l u d i ng  b r en tu x im ab  v edo t in  i n  t h e  t r e a tm en t  o f  n ew ly  d i agn o s ed ,  CD30 -po s i t iv e  
m a tu r e  T -c e l l  lym ph om a s .  Th e  s t an d a rd  o f  c a r e  i n  t h i s  p a t i en t  popu l a t i on  con s i s t s  o f  6 -8  cy c l e s  o f  CHOP  
ch em o th e r apy  ( cy c l oph o s ph am i d e ,  dox o ru b i c i n ,  v i n c r i s t in e ,  an d  p r edn i s on e ) .  P a t i en t s  w i l l  b e  r an dom i z ed  in  a  
S t u dy  SGN35 -014   C l in i c a l  P ro t o co l     Am en dm en t  5 ;  12 -D e c em b e r -2018  
B r en t u x im ab  v edo t i n   S e a t t l e  G en e t i c s ,  In c .  -  C on f i d en t i a l   P ag e  4  o f  68  1 : 1  m an n e r  t o  r e c e i v e  21 -d ay  cy c l e s  o f  t r e a tm en t ,  e i th e r :  6 - 8  cy c l e s  o f  CHOP  o r  6 -8  cy c l e s  o f  b r en t ux im ab  
v edo t i n  p l u s  CHP  (A+CHP ) .  A  t a rg e t  o f  8  cy c l e s  o f  s tu dy  t r e a tm en t  w i l l  b e  adm in i s t e r ed ,  p e r  i n v e s t ig a t o r  
d e c i s i on ,  b a s ed  on  p a t i en t -s p e c i f i c  ch a r a c t e r i s t i c s ,  in c lu d i ng  s t ag e  o f  d i s e a s e  an d  IP I  r i s k  s co r e .  
Br en t u x im ab  v edo t i n  o r  v in c r i s t i n e  w i l l  b e  d i s p en s ed  a s  a  p l a c ebo -con t ro l l ed  dou b l e -dumm y  an d  adm in i s t e r ed  
t o  p a t i en t s  in  a  b l i n d ed  m ann e r .  P l a c eb o  r e p l a c em en t s  f o r  b r e n t ux im ab  v edo t in / v i n c r i s t in e  w i l l  b e  p r ep a r e d  by  
t h e  ph a rm a c i s t  a t  e a ch  s tu dy  s i t e  an d  a  ph a rm a cy  b l in d  w i l l  b e  en f o r c ed .  
S a f e ty  w i l l  b e  m on i t o r ed  ov e r  t h e  cou r s e  o f  th e  s tu dy  by  an  In d ep en d en t  D a t a  Mon i t o r i ng  C omm i t t e e  ( IDMC ) .  
T e s t  P rodu c t ,  Do s e ,  and  Mod e  o f  Adm in i s t ra t i on  
P a t i en t s  w i l l  b e  r an dom i z ed  1 :1  t o  r e c e i v e  6 -8  cy c l e s  o f  s tu dy  t r e a tm en t  (num b e r  o f  cy c l e s  p e r  i n v e s t ig a t o r  
d e c i s i on ) ,  e i t h e r :  
S t an da r d -o f -ca r e  a rm :  Cy c l oph o s ph am i d e  750  m g /m 2,  dox o ru b i c i n  50  m g /m 2,  b l in d ed  v in c r i s t in e  1 .4  m g /m 2 
(do s e  c app e d  a t  2  m g )  adm in i s t e r ed  IV  on  D ay  1  o f  e a ch  cy c l e ;  p r edn i s on e  100  m g  d a i ly  adm i n i s t e r ed  o r a l ly  on  
D ay s  1 −5  o f  e a ch  cy c l e .  P l a c ebo  r ep l a c em en t  f o r  b r en t ux im ab  v edo t i n  w i l l  a l s o  b e  adm in i s t e r ed  IV  i n  a  b l i n d ed  
m ann e r  on  D ay  1  o f  e a ch  cy c l e .  
E xp e r im en t a l  a rm :  B l i n d ed  b r en t ux im ab  v edo t i n  1 .8  m g /k g ,  cy c l oph o s ph am i d e  750  m g /m 2,  dox o ru b i c i n  
50  m g /m 2,  adm in i s t e r ed  IV  on  D ay  1  o f  e a ch  cy c l e ;  p r edn i s on e  100  m g  d a i ly  adm i n i s t e r ed  o r a l l y  on  D ay s  1 −5  
o f  e a ch  cy c l e .  P l a c ebo  r e p l a c em en t  f o r  v in c r i s t i n e  w i l l  a l s o  b e  adm in i s t e r ed  IV  i n  a  b l i n d ed  m ann e r  on  D ay  1  o f  
e a ch  cy c l e .  
Du ra t i on  o f  T r ea tm en t  
S t u dy  t r e a tm en t  con s i s t s  o f  6 -8  cy c l e s  o f  m u l t i ag en t  ch em o th e r apy .  Th e  m ax im um  t o t a l  du r a t i on  o f  th e r apy  i s  
8  cy c l e s ,  o r  app r ox im a t e ly  6  m on th s .  
E f f i ca cy  A s s e s sm en t s  
Ly m ph om a  r e s pon s e  an d  p rog r e s s i on  w i l l  b e  a s s e s s ed  u s ing  t h e  R ev i s ed  R e s pon s e  C r i t e r i a  f o r  M a l i gn an t  
Lym ph om a  (Ch e s on  2007 ).  R ad i og r aph i c  d i s e a s e  ev a l u a t i on s ,  i n c lu d i ng  CT  s c an s  o f  n e ck ,  ch e s t ,  abdom en  an d  
p e l v i s ,  w i l l  b e  a s s e s s ed  a t  b a s e l i n e ,  a f t e r  Cy c l e  4  o f  t r e a tm en t ,  a f t e r  t h e  com p l e t i on  o f  s tu dy  t r e a tm en t ,  a t  9 ,  12 ,  
15 ,  1 8 ,  2 1  an d  24  m on th s  a f t e r  i n i t i a t i on  o f  s tu dy  t r e a tm en t ,  an d  ev e ry  6  m on th s  th e r e a f t e r  u n t i l  d i s e a s e  
p rog r e s s i on ,  p a t i en t  d e a th ,  o r  an a ly s i s  o f  t h e  p r im a ry  en dpo i n t ,  w h i ch ev e r  com e s  f i r s t .  A  CT  s c an  w i l l  a l s o  b e  
p e r f o rm ed  a t  th e  t im e  o f  su s p e c t ed  c l i n i c a l  p rog r e s s i on .  A  PET  s c an  i s  r equ i r ed  a t  b a s e l i n e ,  a f t e r  Cy c l e  4 ,  an d  
a f t e r  t h e  com p l e t i on  o f  s t u dy  t r e a tm en t .  S u b s equ en t  r e s t ag e  a s s e s sm en t s  (CT  s c an s  on ly )  w i l l  b e  p e r f o rm ed  
a c co rd i n g  t o  t h e  c a l en d a r ,  r e l a t i v e  t o  t h e  f i r s t  do s e  o f  s t u dy  t r e a tm en t ,  t o  en su r e  t h a t  tum o r  p rog r e s s i on  i s  
u n i f o rm ly  a s s e s s ed  b e tw e en  th e  t r e a tm e n t  a rm s .  
Ph a rm a cok in e t i c /Ph a rm a cod yn am i c / Immun og en i c i ty  A s s e s sm en t s  
S e rum  con c en t r a t i on s  o f  b r en tu x im ab  v edo t in ,  an t i t h e r ap eu t i c  an t i bod i e s  (ATA )  t o  b r en t ux im ab  v edo t i n ,  an d  
f r e e  d ru g  (m on om e thy l  au r i s t a t i n  E ;  MMAE )  w i l l  b e  m e a s u r ed .  Ph a rm a cody n am i c  a s s e s sm en t s  in c lu d e  t h e  
m e a su r em en t  o f  s o l u b l e  CD30 .  
S a f e ty  A s s e s sm en t s  
S a f e ty  a s s e s sm en t s  w i l l  con s i s t  o f  t h e  su rv e i l l an c e  an d  r e co rd i n g  o f  adv e r s e  ev en t s  (AE s )  an d  m e a su r em en t s  o f  
phy s i c a l  ex am in a t i on  f in d i ng s  an d  l abo r a t o ry  t e s t s .  
S ta t i s t i ca l  M e th od s  
 
 
 
 
 
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 5 of 68  
Interim Analysis  
 The IDMC will provide recommendations to the sponsor as to appropriate study 
direction.  
Safety Analysis  
An IDMC will review safety data on an ongoing basis.  
Endpoints  
The primary efficacy endpoint of this study is PFS by IRF.  
Secondary  endpoints are:  
● PFS per IRF for patients with sALCL  
● Complet e remission ( CR) rate per IRF following the completion of study treatment  
● OS 
● Objective response rate ( ORR ) per IRF following the completion of study treatment  
● Type, incidence, severity, seriousness, and relatedness of adverse events  
● Laboratory abnormalitie s 
 
Additional endpoints are:  
● Incidence of ATA to brentuximab vedotin 
● MRU based on the number of medical care encounters  
● Quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) core 
quality of life questionnaire (Q LQ-C30)  and European Quality of Life 5 -Dimensional (EQ -5D) 
Analysis Methods  
For the primary efficacy analysis, the stratified log -rank test will be used to compare the difference of PFS 
between the 2 treatment groups . Estimation of the hazard ratio will be  based upon the stratified Cox regression 
model . PFS will also be summarized using the Kaplan -Meier method . Similar methods will be used for the 
secondary efficacy endpoint s of OS  and PFS in patients with sALCL . For the primary analysis, PFS will not be 
censored for post treatment radiotherapy, post treatment chemotherapy for the purpose of mobilizing peripheral blood stem cells, or consolidative autologous or allogeneic SCT because these interventions are not administered to treat progressive disease.  
 
 

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 6 of 68 TABLE OF CONTENTS  
PROTOCOL SYNOPSIS  ....................................................................................................................................... 2  
LIST OF ABBREVIATIONS AND DEFINITIONS OF  TERMS  ......................................................................... 9  
1 INTRODUCTION ......................................................................................................................................... 11 
1.1 CD30 -Positive Mature T -Cell Lymphomas  ........................................................................................ 11 
1.2 Frontline Therapy for Mature T -cell Lymphomas  .............................................................................. 12 
1.3 Clinical Experience with Brentuximab Vedotin  ................................................................................. 12 
1.4 Rationale for Brentuximab Vedotin in Combination with CHP  ......................................................... 13 
2 OBJECTIVES  ............................................................................................................................................... 14 
2.1 Primary Obje ctive  ............................................................................................................................... 14 
2.2 Secondary Objectives  ......................................................................................................................... 14 
2.3 Additional Objectives  ......................................................................................................................... 14 
2.4 Endpoints  ............................................................................................................................................ 14 
2.4.1  Primary Endpoint  ................................................................................................................. 14 
2.4.2  Secondary Endpoints  ............................................................................................................ 15 
2.4.3  Additional Endpoints  ............................................................................................................ 15 
3 INVESTIGATIONAL PLAN  ....................................................................................................................... 15 
3.1 Summary of Study Design  .................................................................................................................. 15 
3.2 Discussion and Rationale for Study Design ........................................................................................ 16 
3.2.1  Method of Assigning Patients to Treatment Groups  ............................................................ 17 
3.2.2  Rationale for Selection of Doses  .......................................................................................... 17 
3.2.3  Blinding  ................................................................................................................................ 17 
4 STUDY POPULATION................................................................................................................................ 18 
4.1 Inclusion Criteria  ................................................................................................................................ 18 
4.2 Exclusion Criteria  ............................................................................................................................... 19 
4.3 Removal of Patients From Therapy or Assessment  ............................................................................ 20 
4.3.1  Discontinuation of Study Drug  ............................................................................................. 20 
4.3.2  Patient Withdrawal From Study  ........................................................................................... 21 
5 TREATMENTS  ............................................................................................................................................ 21 
5.1 Treatments Administered .................................................................................................................... 21 
5.2 Investigational Study Drug  ................................................................................................................. 21 
5.2.1  Description  ........................................................................................................................... 21 
5.2.2  Method of Procurement  ........................................................................................................ 21 
5.2.3  Dose and Administration  ...................................................................................................... 22 
5.2.4  Required Premedication and Postmedication  ....................................................................... 22 
5.2.5  Management of Infusion Reactions  ...................................................................................... 22 
5.2.6  Management of Suspected PML .......................................................................................... 23 
5.2.7  Storage and Handling  ........................................................................................................... 23 
5.2.8  Packaging and Labeling  ....................................................................................................... 23 
5.2.9  Preparation  ........................................................................................................................... 23 
5.3 Vincristine  .......................................................................................................................................... 24 
5.3.1  Description  ........................................................................................................................... 24 
5.3.2  Meth od of Procurement  ........................................................................................................ 24 
5.3.3  Dose and Administration  ...................................................................................................... 24 
5.3.4  Required Premedication and Postmedication  ....................................................................... 24 
5.3.5  Storage and Handling  ........................................................................................................... 24 
5.3.6  Packaging and Labeling  ....................................................................................................... 25 
5.3.7  Preparation  ........................................................................................................................... 25 
5.4 Cyclophosphamide, Doxorubicin, and Prednisone  ............................................................................. 25 
5.4.1  Description  ........................................................................................................................... 25 
5.4.2  Method of Procurement  ........................................................................................................ 25 
5.4.3  Dose and Administration  ...................................................................................................... 25 
5.4.4  Required Premedication and Postmedication  ....................................................................... 25 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 7 of 68 5.4.5  Packaging and Labeling  ....................................................................................................... 26 
5.4.6  Preparation  ........................................................................................................................... 26 
5.4.7  Storage and Handling  ........................................................................................................... 26 
5.5 Dose Modifications ............................................................................................................................. 26 
5.6 Concomitant Therapy  ......................................................................................................................... 27 
5.6.1  Required Concomitant Therapy  ........................................................................................... 27 
5.6.2  Allowed Concomitant Therapy  ............................................................................................ 27 
5.6.3  Prohibited Concomitant Therapy  ......................................................................................... 27 
5.7 Treatment Compliance  ....................................................................................................................... 27 
6 STUDY ACTIVITIES  ................................................................................................................................... 27 
6.1 Schedule of Events  ............................................................................................................................. 27 
6.2 Screening Visit (Day -28 to 1)  ............................................................................................................ 28 
6.2.1  Baseline Visit (Day -7 to Day 1)  .......................................................................................... 28 
6.3 Treatment Period (21 -day cycles)  ....................................................................................................... 28 
6.3.1  Every Cycle: Day 1  .............................................................................................................. 28 
6.3.2  Cycles 1 and  2 Only: Day 3  .................................................................................................. 29 
6.3.3  Cycle 4 Only: Day 15 -21...................................................................................................... 29 
6.3.4  Last Planned Cycle of Treatment: Day 15 -21 ...................................................................... 29 
6.4 End-of-Treatment Visit (30 -37 days  after last dose of study drug)  .................................................... 29 
6.5 Follow -up ........................................................................................................................................... 30 
6.6 End of Study/End of Follow -up .......................................................................................................... 31 
7 STUDY ASSESSMENTS  ............................................................................................................................. 31 
7.1 Screening/Baseline Assessments  ........................................................................................................ 31 
7.1.1  CD30 Expression and Histologic Subtype  ........................................................................... 31 
7.2 Response/Efficacy Assessments  ......................................................................................................... 32 
7.3 Pharmacokinetic, Pharmacodynamic, and Immunogenicity Assessments  .......................................... 33 
7.3.1  Biopsy Tissue for Exploratory Correlative Stud ies .............................................................. 33 
7.3.2  Biospecimen Samples for Future Research  .......................................................................... 34 
7.4 Medical Resource Utilization Data Collection  ................................................................................... 34 
7.5 Patient- Reported Outcomes  ................................................................................................................ 34 
7.5.1  EQ-5D – Utility Measurement  ............................................................................................. 34 
7.5.2  FACT/GOG- NTX ................................................................................................................ 34 
7.5.3  QLQ -C30 .............................................................................................................................. 35 
7.6 Safety Assessments ............................................................................................................................. 35 
7.6.1  Adverse Events  ..................................................................................................................... 35 
7.6.2  Clinical Laboratory Tests  ..................................................................................................... 40 
7.6.3  ECOG Performance Status  ................................................................................................... 40 
7.6.4  TNSn  .................................................................................................................................... 40 
7.6.5  Monitoring of Patients with Hepatitis  .................................................................................. 40 
7.7 Appropriateness of Measurements ...................................................................................................... 40 
8 DATA QUALITY CONTROL  AND QUALITY ASSURANCE  ................................................................ 41 
8.1 Site Training and Monitoring Procedures  ........................................................................................... 41 
8.2 Data Management Procedures  ............................................................................................................ 42 
8.3 Access to Source Data  ........................................................................................................................ 42 
8.4 Accuracy and Reliability of Data ........................................................................................................ 43 
8.5 Quality Assurance Procedures  ............................................................................................................ 43 
8.6 Data Handling and Record Keeping  ................................................................................................... 43 
8.6.1  Data Handling  ...................................................................................................................... 43 
8.6.2  Investigator Record Retention  .............................................................................................. 43 
9 DATA ANALYSIS METHODS ................................................................................................................... 44 
9.1 Determination of Sample Size  ............................................................................................................ 44 
9.2 Study Endpoint Definitions  ................................................................................................................ 44 
9.2.1  Primary Endpoint: PFS per IRF ........................................................................................... 44 
9.2.2  Secondary Efficacy Endpoints  ............................................................................................. 45 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 8 of 68 9.2.3  Additional Endpoints  ............................................................................................................ 45 
9.3 Statistical and Analytical Plans  .......................................................................................................... 46 
9.3.1  General Considerations  ........................................................................................................ 46 
9.3.2  Patient Disposition  ............................................................................................................... 48 
9.3.3  Patient Characteristics  .......................................................................................................... 48 
9.3.4  Treatment Compliance  ......................................................................................................... 48 
9.3.5  Efficacy Analyses  ................................................................................................................. 48 
9.3.6 Pharmacokinetic and Pharmacodynamic Analyses  .............................................................. 49 
9.3.7  Health Outcomes Analyses  .................................................................................................. 49 
9.3.8  Safety Analyses  .................................................................................................................... 49 
9.3.9  Interim Analysis  ................................................................................................................... 50 
10 INFORMED CONSENT, ETHICAL REVIEW, AND RE GULATORY CONSIDERATI ONS  ................. 50 
10.1 Informed Consent  ............................................................................................................................... 50 
10.2 Ethical Review  .................................................................................................................................... 50 
10.3 Regulatory Considerations .................................................................................................................. 51 
10.3.1  Investigator Information  ....................................................................................................... 51 
10.3.2  Protocol Amendments and Study Termination .................................................................... 51 
10.4 Study Documentation, Privacy and Records Retention  ...................................................................... 51 
10.5 Clinical Trial Agreement  .................................................................................................................... 52 
11 REFERENCES  .............................................................................................................................................. 53 
APPENDIX A: STUDY SCHEDULE  ................................................................................................................. 55 
APPENDIX B: ECOG PER FORMANCE STATUS  ........................................................................................... 56 
APPENDIX C: INTERNATIONAL PROGNOSTIC INDEX FOR NHL  ........................................................... 57 
APPENDIX D: INVESTIGATOR SIGNATURE PAGE  .................................................................................... 58 
APPENDIX E: DOCUMENT  HISTORY ............................................................................................................ 59 
 
LIST OF IN -TEXT TABLES 
Table 1:  Study treatment by study arm  ........................................................................................................ 21 
Table 2:  Recommended dose modifications for treatment -associated neuropathy  ...................................... 26 
Table 3:  Pharmacokinetic, pharmacodynamic, and immunogenicity sampling time points  ........................ 33 
 
LIST OF IN -TEXT FIGU RES 
Figure 1: Study design  .......................................................................................................................................... 16 
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 9 of 68 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
A+CHP  brentuximab vedotin (ADC ETRIS®), cyclophosphamide, doxorubicin, and prednisone  
ADC  antibody drug conjugate  
AE adverse event  
AITL  angioimmunoblastic T -cell lymphoma  
ALK  anaplastic lymphoma kinase  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
AST  aspartate aminotransferase  
ATA  antitherapeutic antibodies  
ATLL  adult T -cell leukemia/lymphoma  
AUC  area under the concentration -time curve  
β-hCG  beta human chorionic gonadotrophin  
CBC  complete blood count  
Ceoi concentration at the end of infusion  
CFR  Code of Federal Regulations  
CHOP  cyclophosphamide, doxorubicin, vincristine, and prednisone  
CHOP -21 cyclophosphamide, doxorubicin, vincristine, and prednisone  administered every 21 days  
CHP cyclophosphamide, doxorubicin, and prednisone  
Cmax maximum concentrati on 
CNS  central nervous system  
CR complete remission  
CRF  case report form  
CT computed tomography  
Ctrough trough concentration  
EATL  enteropathy -associated T -cell lymphoma  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EFS event -free survival  
EMA  European Medicines Agency  
EOT  end of treatment  
EQ-5D European Quality of Life 5 -Dimensional  
FACT /GOG -NTX  Functional Assessment of Cancer Therapy /Gynecologic Oncology Group – Neurotoxicity  
FDA  Food and Drug Administration  
FDG  fluorodeoxyglucose  
GCP  Good Clinical Practice  
HEENT  head, eyes, ears, nose, and throat  
HIPAA  Health Information Portability and Accountability Act  
HIV human immunodeficiency virus  
HR hazard ratio  
HRA  Health Regulatory Authority  
HTLV -1 human T -cell leukemia virus -1 
ICH International Conference on Harmonisation  
IV intravenous  
IDMC  Independent Data Monitoring Committee  
IPI International Prognostic Index  
IEC Independent Ethics Committee  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 10 of 68 IND investigational new drug  
INN International Nonproprietary Name  
IRB Institutional Review Board  
IRF independent review facility  
JCV John Cunningham virus  
LDH  lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
MF mycosis fungoides  
MMAE  monomethyl auristatin E  
MRI  magnetic resonance imaging  
MRU  medical resource utilization  
MTD  maximum tolerated dose  
MUGA  multi -gated acquisition  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
NHL  non-Hodgkin lymphoma  
NK natural killer  
ORR  objective response rate  
OS overall survival  
PCP Pneumocystis jiroveci  pneumonia  
PCR  polymerase chain reaction  
PD pharmacodynamics  
PD progressive disease  
PET positron  emission tomography  
PFS progression -free survival  
PK  pharmacokinetics  
PML  progressive multifocal leukoencephalopathy  
PR partial remission  
PRO  patient -reported outcome  
PTCL  peripheral T -cell lymphoma  
QLQ -C30 EORTC core quality of life questionnaire  
SAE  serious adverse event  
sALCL  systemic anaplastic large cell lymphoma  
SAP statistical analysis plan  
SCT stem cell transplant  
TNSn  Total Neuropathy Score -nurse  
Tmax time at which the maximum concentration occurs  
ULN  upper limit of normal  
USAN  United States  adopted name  
USP United States Pharmacopeia  
WHO  World Health Organization  
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Bren tuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 11 of 68 1 INTRODUCTION  
Brentuximab vedotin is a CD30- directed antibody -drug conjugate (ADC) consisting of 
3 components : 1) the chimeric IgG1 antibody cAC10, specific for human CD30; 2) the 
microtubule- disrupting agent monomethyl auristatin E (MMAE); a nd 3) a protease- cleavable 
linker that covalently attaches MMAE to cAC10 . The anticancer activity of brentuximab 
vedotin is due to the binding of the ADC to CD30-expressing cells, followed by 
internalization of the ADC -CD30 complex, and the release of MMAE via proteolytic 
cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic death of the cell. 
This is a randomized, double-blind, placebo-controlled, multicenter, phase 3 cl inical trial 
designed to evaluate the efficacy and safety of including brentuximab vedotin in the 
treatment of patients with newly diagnosed, CD30- positive mature T -cell lymphomas . The 
standard of care in this patient population consists of 6- 8 cycles of CHOP chemotherapy 
(cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients will be randomized in a 1:1 manner to receive 21 -day cycles of outpatient treatment, either: 6-8 cycles of CHOP or 
6-8 cycles of brentuximab vedotin (ADCETRIS
®) plus CHP (cyclophosphamide, 
doxorubicin, and prednisone), known as A+CHP. 
1.1 CD30 -Positive Mature T -Cell Lymphomas  
T-cell lymphomas are a subset of aggressive non -Hodgkin lymphomas (NHL) that comprise 
approximately 10-15% of all newly diagnosed cases of NHL in the United States . According 
to the 2008 World Health Organization (WHO) Classification schema, there are 18 subtypes 
of mature T - and natural killer (NK) cell neoplasms (Swerdlow 2008). Various subtypes of 
T- and NK-cell lymphomas are known t o express the cell surface marker CD30; most 
notably, sALCL, in which CD30 expression is a hallmark of the diagnosis ( Savage 2008). 
CD30 -positive mature T -cell lymphomas, including sALCL, peripheral T- cell lymphoma – 
not otherwise specified (PTCL- NOS), angioimmunoblastic T -cell lymphoma (AITL) and 
others, are aggressive lymphoid neoplasms that often present with advanced stage, 
symptomatic disease . These difficult -to-treat lymphomas are often grouped together for 
enrollment in clinical trials based on their universally dismal outcomes . Five -year overall 
survival (OS) in the over 1,300- patient International Periphe ral T -Cell and Natural 
Killer/T -Cell Lymphoma Study was poor and ranged from 12 to 49% depending on 
histologic subtype ( Vose 2008). Five -year failure -free survival, defined as time from initial 
diagnosis to progression, relapse after response, or death resulting from any cause, ranged from 6 to 36%. Other studies have reported CR rates to CHOP therapy between 40 -50% 
(Mercadal 2008; Simon 2010). These data confirm 2  distinct unmet needs. First, there is a 
failure to induce a high rate of initial complete remissions (CRs), and second, those patients who do respond to combination chemotherapy experience disease progression at an unacceptably high rate. Increasing the proportion of patients achieving and maintaining CRs may result in a clinically meaningful improvement in progression -free survival (PFS) and 
OS. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 12 of 68 1.2 Front line Therapy for Mature T- cell Lymphomas  
Frontline treatment of mature T -cell and NK -cell neoplasms is dependent on the subtype of 
disease and often includes clinical trials as the preferred therapeutic option ( NCCN 2013). 
For most subtypes, anthracycline- based multiagent chemotherapy regimens such as CHOP 
are commonly utilized . The notable exception is extranodal NK/T-cell lymphoma, nasal and 
non-nasal t ypes, where concurrent chemoradiotherapy regimens are employed.  
Although no randomized studies have been conducted to establish the use of CHOP in 
patients with CD30 -positive mature T -cell neoplasms, it is the most commonly used regimen 
in the frontline treatment of these patients . The International Peripheral T- Cell and Natural 
Killer/T -Cell Lymphoma Study results indicate that over 85% of patients were treated with 
an anthracycline- based multiagent chemotherapy regimen (Vose 2008 ). In published studies 
that have compared new treatment approaches to an established standard of care, CHOP administered every 3 weeks (CHOP-21) has been used as the control arm ( Simon 2010). In 
addition, published guidelines recommend enrollment into a clinical trial or CHOP as appropriate frontline treatment options for patients with a diagnosis of “peripheral T -cell 
lymphoma, noncutaneous” ( NCCN 2013). Guidelines support administration of 6 cycles of 
CHOP therapy for patients with Stage I -II disea se and International Prognostic Index (IPI) 
score of 0 –2, and 6–8 cycles of CHOP therapy for Stage I -II patients with an IPI score of 3 –5 
and all Stage III -IV patients (Schmitz 2010; NCCN 2013). Comparison of non-randomized 
clinical trials does not support a difference in activity between 6 or 8 cycles of CHOP, with 6–8 cycles commonly employed in clinical practice (Coiffier 2002; Schmitz 2010). As 
mentioned above, the response to CHOP chemotherapy is suboptimal with CR rates ranging from approximately 40-50%, and overall response rates of approximately 75% ( Mercadal 
2008; Simon 2010; Dearden 2011). The estimates of long -term outcome in the mature T -cell 
lymphoma population, regardless of the backbone of anthracycline- based multiagent 
chemotherapy, are suboptimal with a median EFS or PFS of 12–18 months and a media n OS 
of less than 4 years (depending on histologic subtype and IPI score ). 
The high rate of subsequent disease progression among patients responding to frontline therapy led some researchers to employ autologous stem cell transplant (SCT) as a means of improving long-term outcomes; however, no randomized studies have been conducted. 
National and international guidelines support observation, a clinical trial, or the use of autologous SCT as acceptable options for patients who achieve a CR following frontline therapy (Dearden 2011; NCCN 2013). 
1.3 Clinical Experience with Brentuximab Vedotin 
The clinical safety data observed in the phase 1 dose-escalation study (Study SG035-0001) of brentuximab vedotin administered once every 3 weeks support the 1.8 mg/kg dose level as the maximum tolerated dose (MTD) and this dose and schedule was selected for pivotal 
phase 2 studies. In this phase 1 study, the most frequent adverse events (AEs) were nervous system (peripheral neuropathy), constitutional (fatigue and pyrexia), gastrointes tinal 
(diarrhea, nausea), and hematologic (neutropenia) ( Younes 2010). 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 13 of 68 The clinical safety and activity of brentuximab vedotin 1.8 mg/kg administered every 
3 weeks were further evaluated in a pivotal phase 2 study of patients with relapsed or 
refractory sALCL ( Study SG035-0004). In this study, all patients had previously received at 
least 1 prior regimen of multiagent systemic chemotherapy with curative intent. The majority of patients had a diagnosis of ALK- negative disease (72%); relative to the most recent 
therapy, 50% of patients were refractory . Additionally, approximately 60% of patients had 
primary refractory disease, defined as failure to achieve a complete remission (CR) with frontline therapy or progression within 3 months of completing frontline therapy, and 22% of patients had never achieved a response with any previous therapy. In this study of highly refractory patients, the objective response (CR + PR) rate was 86%, with 57% of patients achieving a CR  (Pro 2012). The median duration of response was 12.6 months, and in the 
subset of patients who achieved a CR, the median duration of response was 13.2 months. Brentuximab vedotin was generally well tolerated, with manageable side effects.  
The clinical safety and activity of brentuximab vedotin administered sequentially and 
concurrently with multiagent chemotherapy were evaluated in a phase 1 study in patients with newly diagnosed CD30- positive mature T - and NK-cell neoplasms, including sALCL 
(Study SGN35 -011). This phase 1 study was implemented to determine the safety and 
activity of sequential and combination frontline treatment approaches of brentuximab vedotin with CHOP or CHP chemotherapy. The maximum tolerated dose of brentuximab vedotin was 1.8 mg/kg given concomitantly with CHP. At an interim analysis in this study (data 
presented at the T -Cell Lymphoma Forum 2012), 20 patients in this study had been treated 
with brentuximab vedotin 1.2 or 1.8 mg/kg given concomitantly with CHP for 6 cycles, followed by continued brentuximab vedotin every 3 weeks for up to 10 additional cycles for responding patients. The most common adverse events were nausea, fatigue, and peripheral sensory neuropathy. Of the patients who had a response assessment after 6 cycles of 
brentuximab vedotin plus CHP, 5 of 5 patients achieved a CR.  
A complete summary of the clinical and nonclinical data relevant to brentuximab vedotin and its study in human subjects is provided in the Investigator’s Brochure. 
1.4 Rationale for Brentuximab Vedotin in Combination with CHP  
Because of  the poor outcomes in mature T-cell lymphomas, 2 strategies have been developed 
in an attempt to improve upon the results of CHOP-21: dose escalation of chemotherapy and 
new combinations/new agents. Neither approach to modifying CHOP has resulted in short- 
or long- term benefit to patients . Simon et al. demonstrated in a small randomized study that a 
more aggressive regimen (etoposide, ifosfamide, cisplatin alternating with doxorubicin, bleomycin, vinblastine, dacarbazine; also known as VIP- reinforced -ABVD o r VIP -rABVD) 
was not superior to CHOP-21 in terms of event- free survival . Furthermore, VIP- rABVD 
resulted in more toxicities than CHOP -21. These data confirm that CHOP remains the 
reference regimen in these lymphomas . Another strategy to improve outcome has focused on 
autologous SCT consolidation in patients who achieve CRs at the end of induction therapy. However, many patients are not candidates for SCT, regardless of response to induction 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 14 of 68 therapy, due to age or intercurrent medical conditions. No randomized studies have been 
conducted, and results of single- arm studies are mixed.  
The results of the pivotal phase 2 study in patients with relapsed or refractory disease 
(described in Section 1.3) suggest a marked treatment effect of brentuximab vedotin as monotherapy in sALCL that is anticipated to be both clinically meaningful and associated with a positive risk -benefit ratio when introduced into the f rontline treatment of patients with 
CD30 -positive mature T -cell lymphomas.  
Given the results of treatment with brentuximab vedotin in the relapsed and refractory setting, and its demonstrated safety when combined with CHP, it is hypothesized that a 
treatme nt approach in adults that incorporates brentuximab vedotin as part of multiagent 
frontline induction therapy may yield a PFS and OS benefit. It is also reasonable to evaluate 
the replacement of vincristine with brentuximab vedotin because of the activity previously observed. By replacing a non -targeted microtubule -disrupting agent with a CD30- directed 
ADC  that delivers a potent microtubule-disrupting agent, the potential overlapping toxicities 
of peripheral neuropathy that would be inherent to delivering both agents in the same regimen are avoided.  
2 OBJECTIVES  
2.1 Primary Objective  
● To compare the progression -free survival (PFS) as determined by an independent 
review facility (IRF) between the 2 treatment arms  
2.2 Secondary Objectives 
● To compare the PFS per IRF betwe en the 2 treatment arms for patients with sALCL  
● To compare the remission  rates per IRF following the completion of study treatment 
between the 2 treatment arms  
● To compare overall survival (OS) between the 2 treatment arms  
● To evaluate the safety and tolerability of the 2 treatment arms  
2.3 Additional Objectives  
● To evaluate medical resource utilization (MRU) and calculate utility values  
● To characterize the incidence of  antitherapeutic antibodies (ATA) to brentuximab 
vedotin 
2.4 Endpoints  
2.4.1  Primary Endpoint  
● Progr ession -free survival (PFS) by IRF  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 15 of 68 2.4.2  Secondary Endpoints  
● PFS per IRF for patients with sALCL  
● Complete remission (CR) rate per IRF following the completion of study treatment  
● Overall survival (OS)  
● Objective response rate (ORR) per IRF following the completion of study treatment  
● Type, incidence, severity, seriousness, and relatedness of adverse events 
● Laboratory abnormalities  
2.4.3  Additional Endpoints  
● Incidence of ATA  to brentuximab vedotin 
● MRU based on the number of medical care encounters  
● Quality of life measured b y the European Organisation for Research and Treatment of 
Cancer (EORTC) core quality of life questionnaire (QLQ -C30) and European Quality 
of Life 5 -Dimensional (EQ -5D) 
3 INVESTIGATIONAL PLAN  
3.1 Summary of Study Design  
This is a randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trial 
designed to evaluate the efficacy and safety of including brentuximab vedotin in the 
treatment of newly  diagnosed, CD30- positive mature T -cell lymphomas . The standard of 
care in this patient population consists of 6-8 cycles of CHOP chemotherapy . Patients will be 
randomized in a 1:1 manner to receive 21- day cycles of treatment  in 1 of the following 
2 treatment groups : 
1. Standard -of-care arm : 6–8 cycles of CHOP; or  
2. Experimental arm : 6–8 cycles of brentuximab vedotin plus CHP (A+CHP) 
A target of 8 cycles of study treatment will be administered, per investig ator decision, based 
on patient- specific characteristics, including stage of disease and IPI risk score.  
Brentuximab vedotin or vincristine will be dispens ed as a placebo -controlled double-dummy 
and administered to patients  in a blinded manner (see Table 1 for a list of study treatments by 
arm) . Placebo r eplacements for brentuximab vedotin/vincristine will be  prepared by the 
pharmacist at each study site and a pharmacy blind will be enforced.  
Safety will be monitored over the course of the study by an Independent Data Monitoring Committee ( IDMC ) as describ ed in Section 9.3.9. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 16 of 68 Approximately 450 patients (approximately 225 patients per treatment arm)  will be 
randomized in this study . A study schema is provided in Figure 1. See Appendix A  for a 
schedule of evaluations. 
Figure 1: Study design  
 
a CT and PET sca ns required  
b Additional CT scans every 6 months thereafter until progression  per investigator , death, or analysis of the primary 
endpoint, whichever comes first  
c For patients with documented progression, continued follow -up for survival every 6 months until death or study 
closure, whichever comes first  
3.2 Discussion and Rationale for Study Design 
The primary endpoint of this study, PFS, is one of the endpoints recommended by FDA 
(FDA Guidance for Industry “Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”) and the EMA (“Guideline on the Evaluation of Anticancer Medicinal Products in Man”, CPMP/EWP/205/95/Rev.3/Corr.2) for approval of anticancer drugs . Defined as the 
time from randomization until objective tumor progression or death, PFS is a direct reflection of tumor growth and can be assessed before determination of a survival benefit. Furthermore, because PFS includes deaths from any cause it may be a correlate to overall survival, a secondary endpoint of this study. An additional advantage of PFS is that its determination is not confounded by subsequent therapy. In this study, post treatment radiotherapy, post treatment chemotherapy for the purpose of mobilizing peripheral blood stem cells, or consolidative autologous or allogeneic SC T are not considered subsequent new anticancer 
treatments because they are not administered to treat progressive disease. Standardized criteria will be employed to evaluate progression (Cheson 2007). To ensure consistent 
unbiased application of these criteria, all imaging studies performed to confirm disease sta tus 
and to assess progression during the study will be submitted to an independent third- party 
imaging core laboratory for blinded review and all patients  will have evaluations for 
progression performed on the same schedule. 
Screening/Baseline CT/PET
Randomization 1:1Experimental Arm:
brentuximab vedotin 
plus CHP
(A+CHP)
Standard-of-Care Arm:
CHOPRestagea
Restagea
12 9 18 24bFollow-up 
(including end-of-treatment 
assessments) 
Until progression, death, or analysis of 
the primary endpoint,
whichever comes first
Additional CT restage (months after initiation of 
treatment) for both arms6-8 x 21-day cycles Day -28 to 1
15 21
Survival statuscAt completion of 
study treatment
Cycle 4 
Restagea
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 17 of 68 The current standard of care, CHOP chemotherapy administered for 6 -8 cycles followed by 
either observation and best supportive care, a clinical trial, or an SCT, results in long- term 
disease-free survival in only a minority of patients. Despite this, CHOP is the best available 
therapy i n this population, and the use of CHOP administered for 6- 8 cycles is therefore 
considered appropriate and ethical. The randomized, blinded design of this trial is based on the considerations outlined in the FDA Guidance for Industry “Clinical Trial Endpoi nts for 
the Approval of Cancer Drugs and Biologics” , which states that PFS is ideally evaluated in a 
randomized and blinded study. 
3.2.1  Method of Assigning Patients to Treatment Groups  
Following informed consent and screening assessments, patients will be randomly assigned 
to study treatment in a 1:1 ratio . Randomization will be performed centrally using a system 
that will assign a unique patient randomization number but will not specify the actual treatment assignment . Randomization procedures are detailed in the Study Manual. 
 
  
 
 
3.2.2  Rational
e for Selection of Doses  
In a phase 1 dose-escalation study of brentuximab vedotin ( Study SG035-0001), the MTD 
was defined as 1.8 mg/kg IV admi nistered every 3  weeks . This dose and schedule was further 
evaluated in two pivotal phase 2 studies (Studies SG035-0003 and SG035-0004) in patients 
with CD30 -positive hematologic malignancies.  
In a phase 1 study of brentuximab vedotin (Study SGN35-011), the MTD was defined as 1.8 mg/kg IV administered concomitantly with CHP every 3 weeks.  
3.2.3  Blinding 
A pharmacy blind will be employed in this trial. The adverse event profile of brentuximab vedotin 1.8 mg/kg administered IV once every 3 weeks is not anticipated to be discernable 
from vincristine in this population of aggressive CD30- positive mature T -cell lymphomas.  
Maintaining the blind of the study is crucial for achieving the study objectives. Investigators, patients, IRF, and the sponsor will be blinded to tr eatment assignments, unless otherwise 
specified in the Study Manual. 
Individual treatment assignment will remain blinded even after the primary analysis is 
conducted. Unblinding an individual patient treatment assignment will only occur when one of the fol lowing circumstances is applicable:  
1. At the time of disease progression, a patient’s treatment assignment may be unblinded upon request. A formal unblinding procedure will be followed to provide the study 

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 18 of 68 treatment assignment directly to the patient for the  purpose of further treatment planning 
(see Study Manual).  
2. At the time of study closure, after the primary analysis is completed, the study treatment 
assignment will be provided directly to the patient. 
3. Unblinding a patient’s treatment assignment prior to study closure or disease progression 
must be limited to emergency circumstances where knowledge of the treatment assignment would affect decisions regarding the management of the patient. In the event of such an emergency circumstance, a formal unblinding procedure, carried out by a third party organization, will be followed to allow the investigator to immediately access a patient’s treatment assignment (see Study Manual) . Information on study treatment 
assignment should not be distributed to any other personnel involved in the clinical trial. In the event of any emergency unblinding, Seattle Genetics is to be notified within 24 hours of the occurrence. 
4 STUDY POPULATION  
Eligibility criteria may not be waived by the investigator and are subject to review in the 
event of Good Clinical Practice (GCP) or Health Regulatory Authority (HRA) inspection. Any questions regarding a patient’s eligibility should be discussed with the sponsor’s study 
management group prior to enrollment. 
Patients must meet ALL  of the foll owing inclusion criteria to be eligible for this study:  
4.1 Inclusion Criteria  
1. Patients with newly  diagnosed, CD30- positive mature T -cell lymphomas per the Revised 
European-American Lymphoma WHO 2008 classification by local assessment. See 
Section 7.1.1 for details on definition of CD30 positivity. Eligible histologies are limited 
to the following: 
● ALK -positive sALCL with an IPI score greater than or equal to 2  
● ALK -negative sALCL 
● PTCL -NOS  
● AITL  
● Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T- cell leukemia virus 1)  
● Enteropathy- associated T -cell lymphoma (EATL)  
● Hepatosplenic T -cell lymphoma 
 
2. Fluorodeoxyglucose (FDG)- avid disease by PET and measurable disease of at least 
1.5 cm by CT, as assessed by the site radiologist.  
3. Age greater than or equal to 18 years. 
4. An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.  
S t u dy  SGN35 -014   C l in i c a l  P ro t o co l     Am en dm en t  5 ;  12 -D e c em b e r -2018  
B r en t u x im ab  v edo t i n   S e a t t l e  G en e t i c s ,  In c .  -  C on f i d en t i a l   P ag e  19  o f  68  5 .  T h e  f o l low in g  r e q u i r e d  b a s e l in e  l a b o r a to ry  d a t a :  
● b i l i r u b in  ≤1 . 5X  u p p e r  l im i t  o f  n o rm a l  (ULN )  o r  ≤3X  ULN  f o r  p a t i e n t s  w i th  G i lb e r t ’ s  
d i s e a s e  o r  d o cum e n t e d  h e p a t i c  in v o lv em e n t  w i th  lymp h om a  
● a l a n in e  am in o t r a n s f e r a s e  (ALT )  a n d  a sp a r t a t e  am in o t r a n s f e r a s e  (AS T )  ≤3X  ULN  o r  
≤5X  ULN  f o r  p a t i e n t s  w i th  d o c um e n t  h e p a t i c  in v o lv em e n t  w i th  lymp h om a  
● s e r um  c r e a t in in e  ≤2X  ULN  
● a b so lu t e  n e u t r o p h i l  c o u n t  (ANC )  ≥1 0 0 0 /µL  ( u n l e s s  d o c um e n t e d  b o n e  m a r row  
in v o lv em e n t  w i th  lymp hom a )  
● p l a t e l e t  c o u n t  ≥5 0 , 0 0 0 /µL  ( u n l e s s  d o c um e n t e d  b on e  m a r r ow  in v o lv em e n t  w i th  
lymp h om a )  
 
6 .  F em a l e s  o f  c h i ld b e a r in g  p o t e n t i a l  mu s t  h a v e  a  n eg a t iv e  s e r um  o r  u r in e  b e t a  h um a n  
c h o r io n i c  g o n a d o t r o p h in  (β - hCG )  p r eg n a n cy  t e s t  r e su l t  w i th in  7  d ay s  p r io r  to  th e  f i r s t  
d o s e  o f  s tu dy  t r e a tm e n t  an d  mu s t  a g r e e  to  u s e  a n  e f f e c t iv e  c o n t r a c e p t io n  m e th o d  d u r in g  
th e  s tu dy  a n d  f o r  a t  l e a s t  6  mo n th s  f o l low in g  th e  l a s t  d o s e  o f  s tu dy  d r ug .  F em a l e s  o f  n o n -
c h i ld b e a r ing  p o t e n t i a l  a r e  th o s e  w h o  a r e  p o s tm e n op a u s a l  g r e a t e r  th a n  1  y e a r  o r  w h o  h a v e  
h a d  a  b i l a t e r a l  tu b a l  l ig a t io n  o r  hy s t e r e c t omy .  
7 .  M a l e s  w h o  h a v e  p a r tn e r s  o f  c h i ld b e a r ing  p o t e n t i a l  mu s t  a g r e e  to  u s e  a n  e f f e c t iv e  
c o n t r a c e p t iv e  m e th o d  d u r in g  th e  s tu dy  a n d  f o r  6  mo n th s  f o l low in g  th e  l a s t  do s e  o f  s tu dy  
d r u g .  
8 .  P a t i e n t s  o r  th e i r  l e g a l ly  au th o r i z e d  r e p r e s e n t a t iv e  mu s t  p r o v id e  w r i t t e n  in f o rm e d  c o n s e n t .  
4 .2  Exc lus ion  C r i te r ia  
1 .  H i s to ry  o f  a n o th e r  p r im a ry  in v a s iv e  c a n c e r ,  h em a to lo g i c  m a l ig n a n cy ,  o r  my e lo dy sp l a s t i c  
sy n d r om e  th a t  h a s  n o t  b e e n  in  r em i s s io n  f o r  a t  l e a s t  3  y e a r s .  
2 .  Cu r r e n t  d i ag n o s i s  o f  a ny  o f  th e  f o l low in g :  
● P r im a ry  c u t a n e o u s  CD 3 0 - p o s i t iv e  T - c e l l  lymp h o p r o l i f e r a t iv e  d i so r d e r s  a n d  
lymp h om a s .  Cu t a n e o u s  ALCL  w i th  e x t r a c u t a n e ou s  tumo r  sp r e a d  b ey o n d  lo c o r eg io n a l  
lymp h  n o d e s  i s  e l ig ib l e  (p r e v io u s  s in g l e - ag e n t  t r e a tm e n t  to  a d d r e s s  c u t a n eo u s  a n d  
lo c o r eg io n a l  d i s e a s e  i s  p e rm i s s ib l e )  
● My c o s i s  f u ng o id e s  (MF ) ,  in c lu d in g  t r a n s f o rm e d  MF  
3 .  H i s to ry  o f  p r og r e s s iv e  mu l t i f o c a l  l e u k o e n c e p h a lop a thy  (PML ) .  
4 .  C e r e b r a l /m e n ing e a l  d i s e a s e  r e l a t e d  to  th e  u n d e r ly in g  m a l ig n a n cy .  
5 .  P r io r  t r e a tm e n t  w i th  b r e n tu x im a b  v e d o t in .  
6 .  B a s e l in e  p e r ip h e r a l  n e u ro p a thy  ≥ G r a d e  2  ( p e r  th e  NC I  CTCAE ,  V e r s io n  4 . 0 3 )  o r  
p a t i e n t s  w i th  th e  d emy e l in a t in g  f o rm  o f  Ch a r c o t - M a r i e -T o o th  sy n d r om e .  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 20 of 68 7. Left ventricular ejection fraction less than 45% or symptomatic cardiac disease (including 
symptomatic ventricular dysfunction, symptomatic coronary artery diseas e, and 
symptomatic arrhythmias), or myocardial infarction within the past 6 months , or previous 
treatment with complete cumulative doses of doxorubicin or other anthracyclines. 
8. Any active Grade 3 (per the NCI CTCAE, Version 4.03) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment; any  known 
human immunodeficiency virus (HIV) infection, hepatitis B surface antigen -positive 
status , or known or suspected active hepatitis C infection . 
9. Current therapy with other systemic anti-neoplastic or investigational agents. 
10. Females who are pregnant or breastfeeding.  
11. Patients with a known hypersensitivity to any excipient contained in any of the drug formulations of study treatments.  
12. Patients with known urinary outflow obstruction. 
4.3 Removal of Patients From Therapy or Assessment  
Seattle Genetics or their designee must be notified if a patient is withdrawn from study treatment or from the study . The reason(s) for withdrawal must be documented in the 
patient’s medical records and case report form (CRF) . If a patient discontinues study 
treatment, every attempt should be made to follow the patient until progression, death , or 
administrative study closure . Final assessments will be performed before any other 
therapeutic in tervention if possible. Additionally, any subsequent treatments should be 
documented on the patient’s medical records and CRF. 
4.3.1  Discontinuation of Study Drug  
A patient’s treatment with study drug may be discontinued for any of the following reasons: 
● Complet ed treatment  
● Progressive disease  
● Adverse event  
● Investigator decision 
● Patient decision, Non- AE 
● Study termination by sponsor 
● Other, Non- AE 
 
Patients who discontinue from study treatment will remain on study for follow -up until 
withdrawal from the study (reasons for study discontinuation listed in Section 4.3.2).  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 21 of 68 4.3.2  Patient Withdrawal From Study  
Any patient may be discontinued from the study for any of the  following reasons: 
● Patient withdrawal of consent  
● Study termination by sponsor 
● Lost to follow-up 
● Death  
● Other  
5 TREATMENTS  
5.1 Treatments Administered  
The study treatments to be administered are described in Table 1. 
Table 1: Study treatment by study arm  
Study Treatment in Each 21 -Day Cycle  Experimental 
Arm 
A+CHP  Standard -of-
Care Arm  
CHOP  
Blinded Study 
Drug Aa Brentuximab vedotin  1.8 mg/kg IV on Day 1  X  
Placebo dosing solution IV on Day 1b   X 
Cyclophosphamide 750  mg/m2 IV on Day 1  X X 
Doxorubicin 50 mg/m2 IV on Day 1c X X 
Prednisone 100 mg po daily on Days 1 -5 (±1 day window)  X X 
Blinded Study 
Drug B  Vincristine 1.4 mg/m2 (dose capped at 2 mg) IV on Day 1   X 
Placebo saline IV on Day 1b X  
a Administered within 1 hour of completing treatment with other agents administered via IV  
b Prepared by the site pharmacist; pharmacy blind to be maintained 
c May be administered over up to  48 hours according to institutional standards  
5.2 Investigational Study Drug 
Brentuximab vedotin, the investigational agent under study in this protocol, is an ADC 
consisting of the antibody cAC10, specific for human CD30; the microtubule-disrupting agent MMAE; and a protease- cleavable linker that covalently attaches MMAE to cAC10.  
Detailed information describing the preparation, administration, and storage of brentuximab vedotin is located in the Pharmacy Instructions. 
5.2.1  Description  
Brentuximab vedotin is a sterile, preservative- free, white to off-white lyophilized cake or 
powder supplied by Seattle Genetics in single-use vials for reconstitution for IV 
administration . Each vial of the product contains brentuximab vedotin, trehalose, sodium 
citrate, and polysorb ate 80 . See the Pharmacy Instructions for further information.  
5.2.2  Method of Procurement  
Brentuximab vedotin will be provided by the sponsor. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 22 of 68 5.2.3  Dose and Administration 
The investigational agent will be administered on Day  1 of every 21- day cycle by IV infusion 
given over approximately 30 minutes  (see Table 1) and within 1 hour of completing 
treatment with other agents administered via IV . In the absence of infusion- related reactions, 
the infusion rate for all patients should be calculated in order to achieve a 30-minute infusion 
period. Investigational agent must not be administered as an IV push or bolus. Investigational 
agent  should not be mixed with other medications. 
Dosing is based on patient weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥10% change in weight from baseline. An exception to weight-based dosing is made for patients weighing greater than 100 kg; doses will be based on 100 kg for these individuals. Rounding is permissible within 5% of the nominal dose. 
Dose modifications of the investigational agent are described in Section 5.5. 
5.2.4  Required Premedication and Postmedication  
Routine premedication should not be administered for the prevention of infusion- related 
reactions prior to the first dose of study treatment. However, patients who experience a 
infusion- related reaction may receive subsequent infusions of study treatment with 
premedication as described in Section  5.2.5. Patients who experience a Grade 3 or Grade 4 
infusion- related reaction may potentially continue to receive treatment at the discretion of the 
investigator after discussion with the sponsor. 
Patients should be individually evaluated to assess the need for tumor lysis prophylaxis prior 
to the first dose of investigational agent. Patients should receive prophylaxis as appropriate per the institution al standards. 
5.2.5  Management of Infusion Reactions  
Infusion- related reactions may o ccur during the infusion of study treatment. The infusion 
should be administered at a site properly equipped and staffed to manage anaphylaxis should it occur . All supportive measures consistent with optimal patient care  should be given 
throughout the study according to institutional standards. Supportive measures may include extending the infusion time and/or administering medications for infusion- related reactions.  
Patients who have experienced an infusion- related reaction should be premedicated for 
subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid  administered 30–60 minutes prior to each infusion or according to institutional 
standards. 
If anaphylaxis occurs, study treatment administration should be immediately and 
permanently discontinued. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 23 of 68 5.2.6  Management of Suspected PML  
Signs and symptoms of progressive multifocal leukoencephalopathy (PML) may include 
altered mental status, motor deficits such as hemiparesis or ataxia, visual di sturbances, or 
higher cortical dysfunction such as dysphasia or agnosia. See the Investigator’s Brochure for 
further details.  
If PML is suspected, hold further dosing and undertake a diagnostic work-up including (but not limited to):  
● Neurologic examination s, as warranted  
● Brain radiologic features by magnetic resonance imaging (MRI)  
● PCR analysis : John Cunningham virus (JCV) DNA detectable in cerebrospinal fluid 
 
If PML is confirmed, brentuximab vedotin should be permanently discontinued. 
5.2.7  Storage and Handling 
In this trial, brentuximab vedotin is provided in a blinded study treatment kit, and the 
guidelines for the storage of this kit should be followed per the Pharmacy Manual. 
Refrigeration should be set at 2–8°C for storage of vials and solutions containing 
brentuximab vedotin. The controlled location must be accessible only to the pharmacist or a duly designated person. Brentuximab vedotin does not contain preservatives; therefore, opened and reconstituted vials should be used immediately. If not used immediately, reconstituted vials and solutions must be stored no longer than 24 hours from vial reconstitution  under refrigeration at 2–8°C. It is recommended that vials and solutions be 
protected from direct sunlight until the time of use . Reconstituted vials  and solutions must 
not be shaken. 
Drug accountability instructions are provided in the Pharmacy Manual. 
5.2.8  Packaging and Labeling 
Drug product vials may be labeled as brentuximab vedotin, the United States adopted name 
(USAN) and the Internat ional Nonproprietary Name (INN), or as SGN-35, the compound 
code; the 2 names can be used interchangeably.  
In this study, vials of  brentuximab vedotin will be provided in a blinded kit, which will be 
labeled  to meet country-spe cific regulatory requirements . 
5.2.9  Preparation  
Brentuximab vedotin vials are provided via single- use containers . Any partially used vials or 
diluted dosing solutions should be discarded using appropriate institutional drug disposal procedures. 
Brentuximab vedotin should be reconstituted w ith the appropriate amount of Sterile Water 
for Injection, United States Pharmacopeia (USP) , or equivalent standard. The vial should be 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 24 of 68 gently swirled until the contents are completely dissolved. The vial must not be shaken. The 
reconstituted drug product should be inspected visually for any particulate matter and discoloration. 
The required volume of reconstituted drug product should be diluted into an infusion bag. 
The bag should be gently inverted to mix the solution. The bag must not be shaken. Prior to  
administration, the reconstituted and diluted drug product should be inspected visually for any particulate matter and discoloration.  
For the standard -of-care arm, the pharmacy at the study site must prepare an IV bag 
containing only diluent (e.g., normal saline) . This placebo replacement for brentuximab 
vedotin is to be administered in the same manner as described above and in the Pharmacy Instructions. 
Detailed drug preparation instructions are provided in the Pharmacy Instructions. 
5.3 Vincristine  
5.3.1  Descripti on 
Vincristine is a vinca alkaloid . The mechanism of action is related to the  inhibition of 
microtubule formation in the mitotic spindle . 
5.3.2  Method of Procurement  
Vincristine is commercially available and approved by the United States FDA and other 
regulatory agencies for use in patients with multiple types of cancer . Globally, vincristine 
will be supplied to study sites by the sponsor. 
5.3.3  Dose and Administration 
Vincristine is typically administered as an IV push (see Table 1 for dose), and will be given 
on Day 1 of each 21- day cycle . Dosing should be based on the patient’s baseline (predose, 
Cycle  1 Day  1) height and weight or per institutional standards at the s ite. 
Dose modification guidelines for vincristine are described in Section 5.5. 
5.3.4  Required Premedication and Postmedication  
There are no required pre- or postmedications for vincristine. Routine anti- emetic 
prophylaxis should be administered per institution standard. 5.3.5  Storage and Handling 
In this trial, vincristine is provided in a blinded study treatment kit, and the guidelines for the 
storage of thi s kit should be followed per the Pharmacy Manual and as described in 
Section  5.2.7. Institutional guidelines for the handling of vincristine are to be followed. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 25 of 68 5.3.6  Packaging and Labeling 
Vials of vincristine will be labeled in a blinded kit to meet country -specific regulatory 
requirements.  
5.3.7  Preparation  
Vincristine should be prepared per institutional guidelines. 
For the experimental arm, the site pharmacist will prepare a placebo replacement for 
vincristine (e.g., normal saline) to be administered in the same manner as vincristine.  
5.4 Cyclophosphamide, Doxorubicin, and Prednisone  
5.4.1  Description  
All patients in the study will be administered the cyclophos phamide, doxorubicin, and 
prednisone components of the CHOP regimen. 
Cyclophosphamide is a nitrogen mustard alkylating agent. Doxorubicin is a cytotoxic 
anthracycline antibiotic . Prednisone is a corticosteroid. 
5.4.2  Method of Procurement  
Cyclophosphamide, doxorubicin, and prednisone are commercially available and approved by the United States FDA and other regulatory agencies for use in treating patients with multiple types of cancer.  
In the United States and Canada, cyclophosphamide, doxorubicin, and prednisone will be supplied by the study site and will be billed to patients and/or their third -party payer 
(insurance, a healthcare provider, or applicable government program). 
In Japan, cyclophosphamide and doxorubicin will be supplied by the study site. Prednisone 
will be supplied to study sites by the sponsor. 
In regions outside of the United States , Canada, and Japan, cyclophosphamide, doxorubicin, 
and prednisone will be supplied to study sites by the sponsor. 
5.4.3  Dose and Administration 
Refer to Table 1 for specific doses. Administration of study treatment should be according to 
the institutional stand ard. Dosing should be based on the patient’ s baseline (predose, Cycle 1 
Day 1) height and weight or per institutional standards at the site. 
Dose modification guidelines for cyclophosphamide, doxorubicin, or prednisone are 
described in Section 5.5. 
5.4.4  Required Premedication and Postmedication  
There are no protocol-required pre- or postmedications for cyclophosphamide, doxorubicin, 
and prednisone. Routine anti -emetic prophylaxis should be administered per institution 
standard. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 26 of 68 5.4.5  Packaging and Labeling 
In the United States and Canada, supplies of cyclophosphamide, doxorubicin, and prednisone 
are commercially available. Outside of the United States and Canada, supplies will be labeled to meet country- specific regulatory requirements.  
5.4.6  Preparation  
Cyclophosphamide, doxorubicin, and prednisone should be prepared per institutional guidelines. 
5.4.7  Storage and Handling 
Cyclophosphamide, doxorubicin, and prednisone should be stored and handled per 
institutional guidelines.  
5.5 Dose Modifications  
Table 2 describes the recommended dose modifications for study treatment- associated 
neuropathy. 
Doses reduced for  treatment -related neuropathy should not be re-escalated without discussion 
with the sponsor. 
Table 2: Recommended dose modifications for treatment- associated neuropathy 
Grade of Treatment -
Associated 
Neuropathy  Recommended Dose Modi fication  
Sensory Neuropathy  Motor Neuropathy  
1 Continue study treatment at same dose 
level.  Continue study treatment at same dose 
level.  
   
2 Continue study treatment at the same dose 
level .  Reduce  dose levels of brentuximab 
vedotin/vincristinea. 
   
3 Reduce dose levels of brentuximab 
vedotin/vincristinea.  Discontinue treatment with brentuximab 
vedotin/vincristine.  
   
4 Discontinue treatment with brentuximab 
vedotin/vincristine.  Discontinue treatment with brentuximab 
vedotin/vincristine.  
a To maintain the study blind, dose levels of both blinded study treatments must be reduced as follows : 1.2 mg/kg 
brentuximab vedotin and 1 mg vincristine . No further dose reductions are permitted.  
 
Dose modifications of blinded study treatment (brentuximab vedotin/vincristine), 
cyclophosphamide, doxorubicin, or prednisone due to hematologic and non- hematologic 
toxicity are allowed per institutional standards at the discretion of the investigator . Permitted 
dose modifications include discontinuation of a treatment component. For blinded study treatment, the reduced dose levels are 1.2 mg/kg brentuximab vedotin and 1 mg vincristine. No further dose reductions of brentuximab vedotin or vincristine are permitted. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 27 of 68 5.6 Concomitant Therapy  
All concomitant medications, bloo d products, and radiotherapy  administered will be 
collected from Day 1 (predose) through the safety reporting period. Any concomitant 
medication given for a study protocol- related adverse event should be recorded from the time 
of informed consent. 
5.6.1  Required Concomitant Therapy  
There are no required concomitant therapies.  
5.6.2  Allowed Concomitant Therapy  
Routine premedication for infusion reactions should not be administered prior to the first 
dose of brentuximab vedotin. However, patients who experience an infusion- related reaction 
may receive subsequent treatment with premedication as described in Section 5.2.5. 
Routine infectious prophylaxis for Pne umocystis jiroveci pneumonia (P CP) should be 
considered for all patients.  
The use of transfusions, platelet and/or colony- stimulating factors per institutional practice is 
permitted . Intrathecal prophylactic treatment for cerebral/meningeal disease is perm itted at 
the discretion of the investigator. 
The use of colony- stimulating factors and/or chemotherapy for stem -cell collection to enable 
a future autologous SCT  is permitted per institution standard . Chemomobilization of stem 
cells is only permitted after  EOT procedures are completed.  
Consolidative SCT or r adiotherapy may be given at the investigator’s discretion after EOT 
procedures are completed . At least 6 cycles of study treatment should be given prior to 
initiating post treatment consolidative SCT or radiotherapy.  
5.6.3  Prohibited Concomitant Therapy  
Patients may not receive other investigational drugs, immunosuppressive medications, 
radiotherapy, or systemic anti- neoplastic therapy from Day 1 through EOT . In addition, other 
prohibited concomitant therapies should be excluded in accordance with the approved prescribing information  for each agent . Exceptions are noted in Section 5.6.2. 
5.7 Treatment Compliance  
Study drug  administration is performed by study site staff and documented in source 
documents and the CRF. 
6 STUDY ACTIVITIES  
6.1 Schedule of Events  
Adverse events and c oncomi tant medications will be collected from Day 1 (predose) through 
the safety reporting period . Any study protocol- related adverse event should be recorded 
from the time of informed consent as well as any concomitant medications given for 
S t u dy  SGN35 -014   C l in i c a l  P ro t o co l     Am en dm en t  5 ;  12 -D e c em b e r -2018  
B r en t u x im ab  v edo t i n   S e a t t l e  G en e t i c s ,  In c .  -  C on f i d en t i a l   P ag e  28  o f  68  t r e a tm e n t  o f  th e  ad v e r s e  e v e n t .  A  s c h ed u l e  o f  e v en t s  i s  p r o v id e d  in  A p p e n d ix  A .  S tu dy  
a c t iv i t i e s  a r e  l i s t e d  by  v i s i t  in  th i s  s e c t io n  a n d  d e s c r ip t io n s  o f  a l l  s tu dy  a s s e s sm e n t s  a r e  
p r e s e n t e d  in  S e c t io n  7.  
6 .2  Sc reen ing  V is i t  (Day  -28  to  1 )  
● I n f o rm e d  c o n s e n t  
● S tu dy  e l ig ib i l i ty  p e r  in c lu s io n / e x c lu s io n  c r i t e r i a  
● M e d i c a l  h i s to ry  
● CD 3 0 / h i s t o l o g i c a l  c o n f i rm a t i o n  –  s u bm i s s i o n  o f  t um o r  s p e c im e n  f o r  c e n t r a l  p a t h o l o g y  
c o n f i rm a t i o n  o f  h i s t o l o g y ,  CD 3 0  e x p r e s s i o n ,  a n d  ALK  s t a t u s  ( s e e  S e c t i o n  7 . 1 . 1 )  
● H um a n  T - c e l l  l e u k em i a  v i r u s - 1  ( HTLV -1 )  s t a tu s  ( s e e  S e c t io n  7 . 1 )  
● IP I  s c o r e  ( s e e  S e c t io n  7 . 1 )  
● H emo g lo b in  (Hg b )  A 1 c  ( s e e  S e c t io n  7 . 6 . 2 )  
● CT  o f  c h e s t ,  n e c k ,  a b d om e n ,  p e lv i s  ( s e e  S e c t io n  7 . 2 )  
● PET  s c a n  ( s e e  S e c t io n  7 . 2 )  
● B o n e  m a r r ow  b io p sy  (m ay  b e  o b t a in e d  w i th in  6 0  d ay s  o f  th e  f i r s t  d o s e  o f  s tu dy  
t r e a tm e n t ;  s e e  S e c t io n  7 .2 )  
● E c h o c a r d io g r am  o r  mu l t i - g a t e d  a c q u i s i t io n  (MUGA )  s c a n  (m ay  b e  o b t a in ed  u p  to  6  
mo n th s  p r io r  to  th e  f i r s t  d o s e  o f  s tu dy  t r e a tm e n t )  
6 .2 .1  Base l ine  V is i t  (Day  -7  to  Day  1 )  
● H e ig h t  a n d  w e ig h t  
● E l e c t r o c a r d iog r am  (ECG )  
● P r e g n a n cy  t e s t  f o r  f em a l e s  o f  c h i ld b e a r in g  p o t e n t i a l  ( s e e  S e c t io n  7 . 6 . 2 )  
● ECOG  p e r f o rm a n c e  s t a tu s  ( s e e  S e c t io n  7 . 6 . 3 )  
● S e r um  c h em i s t ry  p a n e l  ( s e e  S e c t io n  7 . 6 . 2 )  
● CBC  w i th  d i f f e r e n t i a l  ( s e e  S e c t io n  7 . 6 . 2 )  
● R a n d om i z a t io n  –  to  o c c u r  a f t e r  e l ig ib i l i ty  i s  d e t e rm in e d  a n d  w i th in  1  b u s in e s s  d ay  o f  
p l a n n e d  f i r s t  d o s e  o f  s tu dy  t r e a tm e n t  
6 .3  T rea tmen t  Pe r iod  ( 21 -day  cyc les )  
6 .3 .1  Eve ry  Cyc le :  Day  1  
● L ymp h om a  a s s e s sm e n t  ( s e e  S e c t io n  7 . 2 ;  c o n d u c t ed  w i th in  ≤4 8  h o u r s  p r io r  to  s tu dy  
t r e a tm e n t  in  Cy c l e  1 )  
● ECOG  p e r f o rm a n c e  s t a tu s  ( n o t  r e q u i r e d  in  Cy c l e  1 )  
● S e r um  c h em i s t ry  
● CBC  w i th  d i f f e r e n t i a l  
● P a t i e n t - r e p o r t e d  o u t c om e  (PRO )  q u e s t io n n a i r e s  –  EQ - 5D ,  QLQ -C3 0 ,  a n d  Fu n c t io n a l  
A s s e s sm e n t  o f  C a n c e r  Th e r a py /Gy n e c o log i c  O n co lo gy  G r o u p  –  N e u r o to x i c i ty  
(FACT /GOG -NTX ;  s e e  S e c t io n  7 . 5 )  
Study SGN35 -014  Clinical Protocol   Amendment  5; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 29 of 68 ● Medical resource utilization (MRU) data collection (see Section 7.4) 
● Total Neuropathy Score- nurse (TNSn) assessment ; every odd-numbered cycle only 
(see Section 7.6.4) 
● Blood samples for pharmacokinetic (PK), pharmacodynamic (PD ) assessment  (see 
Section 7.3 for details)  
● Blood sample for ATA assessment (Cycles 1 -4 only; see Section 7.3 for details ) 
● Study treatment ; administered after all assessme nts have been conducted 
6.3.2  Cycles 1 and 2 Only : Day 3  
● Blood sample for PK assessment 
6.3.3  Cycle 4 Only : Day 15 -21 
● CT of chest, neck, abdomen, pelvis 
● PET scan  
● Bone marrow biopsy to confirm response (if positive at baseline) 
6.3.4  Last Planned Cycle of Treatment : Day 15-21 
The following assessments must be obtained for patients who complete the last planned cycle 
of treatment . Patients who discontinue treatment prior to the planned last cycle of treatment 
should have an EOT visit, as described in Section 6.4. 
● Lymphoma assessment  
● CT of chest, neck, abdomen, pelvis 
● PET scan  
● Bone marrow biopsy to confirm response (if positive at baseline and not found to be negative at a prior restage)  
6.4 End- of-Treatment Visit (30 -37 days after last dose of study drug)  
If EOT evaluations are completed before 30 days after the last study treatment, the patient will be contacted by phone 30- 37 days following the last treatment to assess for adverse 
events.  
EOT assessments will be performed before any other therapeutic intervention, if possible. 
● Pregnancy test for females of childbearing potential 
● Performance status  
● Serum chemistry  
● CBC with differential  
● Blood samples for PK, PD, and ATA assessment  
● PRO questionnaires : EQ-5D, QLQ-C30, and FACT/GOG- NTX  
● MRU data collection  
● TNSn assessment  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 30 of 68 The following response assessments are required if they were not conducted at last cycle of 
treatment : 
● Lymphoma assessment  
● CT of chest, neck, abdomen, pelvis 
● PET scan  
● Bone marrow biopsy to confirm response (if positive at baseline and not found to be negative at a prior restage)  
6.5 Follow -up 
The following a ssessments are required  during follow up at the time points described. 
Months are relative to the first dose of study treatment. Assessments are to be conducted until death or study closure unless otherwise specified. Assessments occurring after 24 months from first dose may be conducted via a phone call. 
● Survival status and subsequent anticancer therapies received  – every 
6 months (+/ -1 week  up to month 30, +/ -1 month after month 30) starting at month  12 
and after disease progression  
● TNSn assessment and FACT/GOG NTX – every 3 months (+/-1 week)  month 9 
through month 24 or until disease progression or initiation of new anticancer therapy ; 
only performed for patient s with treatment-emergent neuropathy ( a treatment -
emergent event is one that is newly occurring or worsening following study treatment; see Section 9.3.8.2)  
● QLQ -C30 questionnaire – every 3 months (+/-1 week) month 9 through month 24 and 
at month 30, or until disease progression 
● MRU data collection  – every 3 months (+/-1 week) month 9 through month 24 and at 
month 30 
● EQ-5D questionnaire – every 3 months (+/-1 week) month 9 through month 24 and 
every 6 months (+/-1 week) thereafter; not required at months 9, 15, and 21 for patients with disease progression  
In addition, (prior to Amendment 5), patients who have not yet experienced disease progression per investigator assessment [based on the Revised Response Criteria for Malignant Lymphoma ( Cheson 2007)], the following assessments must be obtained at 9, 12, 
15, 18, 21, and 24 months (+/-1 week) after the first dose of study treatment, and every 6 months thereafter (+/ -1 week) until progression per investigator, death, or analysis of the 
primary endpoint, whichever comes first.  
● CT of ch est, neck, abdomen, pelvis 
● Lymphoma assessment  
 
After the analysis of the primary endpoint (Amendment 5 and later), patients who have not yet experienced disease progression should continue to be scanned according to the site’s 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 31 of 68 standard of care schedule. If progression occurs, it should be recorded in the CRF. Scans 
should not be sent t o BioClinica.  
6.6 End of Study/End of Follow -up 
The date the patient met criteria for study discontinuation and the reason for study discontinuation will be collected.  
7 STUDY ASSESSMENTS 
7.1 Screening/Baseline Assessments  
Only patien ts who meet all inclusion and ex clusion criteria specified in Section  4 will be 
enrolled in this study.  
Patient medical history includes a thorough review of significant past medical history, current conditions, any treatment for prior malignancies and response to prior treatment, and any concomitant medications.  
Cardiac function will be determined by performing either an echocardiogram or MUGA scan (may be obtained up to 6 months prior to the first dose of study treatment) . 
HTLV -1 status must be obtained by local laboratory assessment to inform the diagnosis. 
IPI score must be determined based on the International Non- Hodgkin Lymphoma 
Prognostic Factors Project ( Shipp 1993). 
7.1.1  CD30 Expression and Histologic Subtype  
Histologically confirmed CD30+ disease and histologic subtype must be determined by local pathology assessment  in a CD30 -qualified laboratory to  enable enrollment . Local pathology 
will also assess ALK status for patients with a diagnosis of sALCL.  
By local assessment, tissue from the diagnostic biopsy must confirm CD30 positivity  by 
immunohistochemistry . The 3  following criteria must be met to dec lare CD30 positivity: 
1. CD30 detected in 10% or greater of neoplastic cells (in cases where enumeration of neoplastic cells is not possible, total lymphocytes may be used). 
2. CD30 staining at any intensity above background. 
3. Membranous, cytoplasmic, and/or golg i pattern of expression of the CD30 antigen. 
Submission of the tumor block or approximately 15 unstained slides from a diagnostic biopsy 
is required prior to randomization  for subsequent central confirmation of CD30 expression, 
disease subtype, and ALK status for patients with a diagnosis of sALCL. The diagnostic specimen must be from a malignant lymph node or extranodal tissue obtained by core or excisional/incisional biopsy . Cutaneous, bone, or bone marrow samples alone are 
unacceptable. Fine needle aspirate and cytology samples are also unacceptable.  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 32 of 68  
 
Details a
nd shipping instructions are provided in the Research Specimen Laboratory Manual. 
7.2 Response/Efficacy Assessments  
Lymphoma assessments are to be performed at the time points outlined in Section 6 and 
Appendix A . An adequate focused lymphoma assessment consists of: 
● Patient medical history, including a thorough review of:  
○ The patient’s current signs and symptoms, including B symptoms (fever, night 
sweats, or weight loss >10%) 
○ Concomitant medications  
● Physical examination, including evaluation of skin, HEENT (head, eyes, ears, nose, 
and throat), lymph nodes, heart, lungs, abdomen, back, extremities, and neurology 
 
Radiographic assessments (CT of chest, neck, abdomen, and pelvis) will be performed at protocol-specified time points or if disease progression is suspected. Assessment of lymphoma progression will be made according to the Revised Response Criteria for Malignant Lymphoma ( Cheson 2007). Tr eatment  decisions by the investigator will be based 
on thes e assess ments . CT and PET scans are required per protocol as directed in Section 6 
and Appendix A . 
A combined CT/PET may be obtained to satisfy the requirements for CT and PET scanning when both are required per protocol, as long as the CT scan is of diagnostic quality. CT and/or PET scans may also be obtained throughout the study if clinically indicated; if scans are performed at non- protocol specified time points, results will be collected in the patient’s 
CRF and images will be submitted for central review.  
A bone marrow biopsy is required at base line. Information from an assessment performed 
within 60 days of the first dose of study treatment, as part of clinical care, may be used to satisfy the baseline bone marrow biopsy requirement. Postbaseline biopsies are required to confirm response if bone marrow is positive at baseline; this confirmation is to be obtained 
within 4 weeks of documentation of response by radiographic assessment. Repeat bone marrow biopsies are not required once bone marrow is found to be negative. 
If cutaneous lesions are the sole site of progressive disease, a biopsy must be obtained to 
histologically confirm progression. 
All patients’ clinical data and tumor images must be available for CRF source verification . 
Copies of all imaging studies must be made available for review by the sponsor (or its 
designee)  and the third party imaging core laboratory. Refer to the Study Manual for details 
(instructions on collecting and submitting tumor imaging studies for third -party imaging core 
laboratory review).  

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 33 of 68 7.3 Pharmacokinetic, Pharmacod ynamic, and Immunogenicity Assessments  
Sensitive, qualified assays will be used to measure drug analytes including brentuximab 
vedotin ADC and MMAE  concentrations in serum or plasma. These assays will include 
enzyme linked immunosorbent assays (ELISA) and liquid chromatography/tandem mass spectrometry (LC -MS/MS) assays, as well as other assays if further characterization is 
required. 
Blood samples for PK  testing will be collected at selected time  points in Cycle s 1 and 2 and 
at predose in subsequent cycles (see Table 3). ATA to brentuximab vedotin will also be 
measured predose at Cycles 1 through 4 and at EOT using an appropriate qualified assay . 
Selected PK parameters to be estimated include concentration at 48 hours from the start of 
infusion, concentration at the end of infusion for brentuximab vedotin (C
eoi), and trough 
concentration (C trough). PK , demographic , and clinical laboratory  data may be inco rporated 
into the brentuximab vedotin population PK model for further model refinement and 
parameter estimation . The incidence of ATA to brentuximab vedotin will also be assessed. 
Blood samples will be collected (predose at each cycle)  for measurement of PD biomarkers 
such as sCD30. 
Table 3 presents the PK/PD and immunogenicity sample collection time  points. All sampling 
times are relative to the start  of brentuximab vedotin infusion, except for the end of infusion 
concentrations. Refer to the Research Specimen Manual for information on collection, 
processing, storage, and shipment of samples. 
Table 3: Pharmacokinetic, pharmacody namic, and immunogenicity sampling time  
points  
Cycle  Study 
Day Time  Window  Relative Timea PK PD ATA  
1-2 Day 1  Pre-dose Within prior 24 hr  Start of infusion  X X X 
 End of infusion  
(30 min)  Within 30 min post  
end of infusion  End of infusion  X   
Day 3 48 hr ± 24 hr  Start of infusion  X   
3+ Day 1  Pre-dose Within prior 24 hr  Start of infusion  X X Xb 
EOT   X X X 
a Relative to infusion of Blinded Study Drug A (brentuximab vedotin or placebo replacement)  
b Cycles 3 and 4 only  
7.3.1  Biopsy Tissue for Exploratory Correlative Studies  
Patients will be asked to participate in optional exploratory correlative studies involving 
tumor tissue . The tumor tissue will be used to conduct exploratory correlative studies such as 
CD30 expression.  
 These optional studies will be conducted on the following tissues: 
● Leftover unstained slides or tumor tissue from the diagnostic biopsy 

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 34 of 68 ● Unstained slides or leftover tissue from a core biopsy obtained as part of standard -of-
care clinical interventions while a patient is participating in the study (e.g. , for 
treatment failure at any time)  
 
No additional procedures will be conducted to obtain these research tissues, and thus no 
additional patient risk is introduced with these optional exploratory correlative studies. 
7.3.2  Biospecimen Samples for Future Research  
In the United States, remaining de-identified unused blood and tissue will be retained by Seattle Genetics and used for future research  for patients who provide additional consent. 
 
 
 Blood and tissue samples donated for future 
research will be retained for a period of 25 years. 
For patients treated outside of the United States, or if additional consent is not granted, any 
blood and tissue samples remaining after all study testing is completed will be destroyed following study closure. 
 
 
7.4 Medical Resource Utilization Data Collection  
All medical care encounters related to lymphoma, treatmen t for ly mphoma, or lymphoma-
related assessments will be collected for all patients . See Appendix A  and Section 6 for 
timing of MRU data collection  and see the Study Manual for detailed guidance. 
7.5 Patient -Reported Outcome s 
Questionnaires will be administered as specified in Appendix A  and Section 6 and must be 
completed prior to administration of study treatment on treatment days . Questionnaires may 
be collected by phone once a patient experiences disease progres sion p er investigator [ based 
on the Revised Response Criteria for Malignant Lymphoma ( Cheson 2007 )] and is in 
survival follow-up. 
7.5.1  EQ-5D – Utility Measurement  
The E uropean Quality of Life (EuroQOL) EQ- 5D is a 5 -item questionnaire with a 
“thermometer” visual analog scale ranging from 0 (worst imaginable health state) to 100 
(best imaginable health state).  
7.5.2  FACT/GOG- NTX 
The FACT/GOG- NTX is a self -administered questionna ire for assessing changes in quality 
of life and assessment of treatment -induced neurologic symptoms (sensory, hearing, motor, 
and dysfunction). Patients score their well -being by selecting the frequency with which they 

Study SGN35 -014  Clinical Protocol   Amendme nt 5; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 35 of 68 associate with a given statement (0 being “not at all ”, up to 4 being “very much”). The 
neurotoxicity subscale consists of 11 questions. 
7.5.3  QLQ -C30 
The EORTC QLQ -C30 is a questionnaire developed to assess the quality of life  of cancer 
patients . The QLQ -C30 incorporates 9 multi- item scales : 5 functional scales (physical, role, 
cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), 
and a global health and quality of life  scale ( Aaronson 1993). 
7.6 Safety Assessments  
The assessment of safety during the course of this study will consist of the surveillance and recording of adverse eve nts (AEs) including serious adverse events (SAEs), recording of 
concomitant medication and measurements of protocol- specified physical examination 
findings and laboratory tests. 
Safety will be monitored over the course of the study by an IDMC  as described in Section 
9.3.9. 
7.6.1  Adverse Events 
7.6.1.1  Definitions  
Adverse Event  
According to the International Conference on Harmonization (ICH) E2A guideline 
Definition s and Standards for Expedited Reporting, and 21 CFR 312.32, IND Safety 
Reporting, an adverse event is any untoward medical occurrence in a patient  or clinical 
investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.  
The following information should be considered when determining whether or not to record a test result, medical condition, or other incident on the Adverse Events and Pre- existing 
Conditions case report form (CRF): 
● From the time of informed consent through the day prior to study Day 1, only study protocol- related adve rse events should be recorded. 
● All medical conditions present or ongoing predose on study Day 1 should be recorded.  
● All adverse events (regardless of relationship to study drug) should be recorded from study Day 1 (during and post dose) through the end of the safety reporting period (see Section 7.6.1.3). Complications that occur in association with any procedure (e.g., 
biopsy) should be recorded as AEs whether or not the procedure was protocol mandated.  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 36 of 68 ● Changes in medical conditions and adverse events, including changes in severity, 
frequency, or character, during the safety reporting period should be recorded. 
● In general, an abnormal laboratory value should not be recorded as an adverse event unless it is associated with clinical signs or symptoms, requires an intervention, results in a serious adverse event, or results in study termination or interruption/discontinuation of study treatment. When recording an adverse event resulting from a laboratory abnormality, the resulting medical condition rather than the abnormality itself should be recorded (e.g., record “anemia” rather than “low hemoglobin”). 
Serious Adverse Events  
An adverse event should be classified as a serious adverse event (SAE) if it meets one of the following criteria:  
Fatal:  Adverse event resulted in death  
 
Life threatening:  The adverse events placed the patient at immediate risk of death. This 
classification does not apply to an adverse event that hypothetically might cause 
death if it were more severe.  
 
Hospitalization:  The AE required or prolonged an existing inpatient hospita lization. 
Hospitalizations for elective medical or surgical procedures or treatments planned before the signing of informed consent in the study or routine check -ups are not 
serious adverse events by this criterion. Admission to a palliative unit or hospic e 
care facility is not considered to be a hospitalization . Hospitalizations or prolonged 
hospitalizations for scheduled therapy of the underlying cancer or study target disease need not be captured as SAEs.  
 
Disabling/ 
incapacitating:  Resulted in a persistent or significant incapacity or substantial disruption of the 
patient’s ability to conduct normal life functions.  
 
Congenital anomaly or 
birth defect:  An adverse outcome in a child or fetus of a patient exposed to the molecule or 
study treatment r egimen before conception or during pregnancy.  
 
Medically significant:  The adverse event did not meet any of the above criteria, but could have 
jeopardized the patient and might have required medical or surgical intervention to prevent one of the outcomes listed above  or involves suspected transmission via a 
medicinal product of an infectious agent.  
Adverse Event Severity  
AE severity should be graded using the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (NCI CTCAE), Version 4.03. These criteria are provided in the 
study manual. 
AE severity and seriousness are assessed independently . ‘Severity’ characterizes the intens ity 
of an AE . ‘Serious’ is a regulatory definition and serves as a guide to the sponsor for defining 
regulatory reporting obligations (see definition for Serious Adverse Events). 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 37 of 68 Relationship of the Adverse Event to Study Treatment  
The relationship of each adverse event to each study treatment [blinded study treatment 
(brentuximab vedotin or vincristine) or any component of CHP] should be evaluated by the 
investigator using the following criteria:  
Related:  There is evidence to suggest a causal relationship between the drug and the adverse 
event, such as:  
● an event that is uncommon and known to be strongly associated  with drug 
exposure (e .g., angioedema, hepatic injury, Stevens -Johnson Syndrome)  
● an event that is not commonly associated with drug exposure, but is otherwise 
uncommon in the population exposed to the drug (e.g., tendon rupture)  
Unrelated:  Another cause o f the adverse event is more plausible  (e.g., due to underlying disease 
or occurs commonly in the study population), or a temporal sequence cannot be 
established with the onset of the adverse event and administration of the study 
treatment, or a causal rela tionship is considered biologically implausible  
7.6.1.2  Procedures for Eliciting and Recording Adverse Events  
Investigator and study personnel will report all AEs and SAEs whether elicited during patient 
questioning, discovered during physical examination, laboratory testing and/or other means by recording them on the CRF and/or SAE form, as appropriate. 
Eliciting Adverse Events  
An open-ended or non-directed method of questioning should be used at e ach study visit to 
elicit the reporting of AEs.  
Recording Adverse Events  
The following information should be recorded on the Adverse Events and Pre- existing 
Conditions CRF: 
● Description including onset and resolution dates 
● Whether it met serious criteria  
● Severity  
● Relationship to study treatment or other causality  
● Outcome 
Diagnosis vs. Signs or Symptoms 
In general, the use of a unifying diagnosis is preferred to the listing out of individual 
symptoms . Grouping of symptoms into a diagnosis should only be done if each component 
sign and/or symptom is a medically confirmed component of a diagnosis as evidenced by standard medical textbooks. If any aspect of a sign or symptom does not fit into a classic 
pattern of the diagnosis, report the individual symptom as a separate adverse event. 
Important exceptions for this study are adverse reactions associated with the infusion of the 
investigational agent. For infusion-related reactions, do not use the NCI CTCAE terms of ‘cytokine release syndrome,’ ‘acute infusion reaction,’ or ‘allergic or hypersensitivity 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 38 of 68 reaction.’  Instead, recor d each sign or symptom as an individual adverse event. If multiple 
signs or symptoms occur with a given infusion-related event, each sign or symptom should 
be recorded separately with its level of severity.  
Recording Serious Adverse Events  
For SAEs, record  the primary event on both the CRF and an SAE form; events occurring 
secondary to the primary event should be described on the SAE form in the narrative description of the case. 
The following should be considered when recording SAEs: 
● Death is an outcome of  an event. The event that resulted in the death should be 
recorded and reported on both an SAE form and CRF. 
● For hospitalizations, surgical, or diagnostic procedures, the illness leading to the 
surgical or diagnostic procedure should be recorded as the SAE, not the procedure itself . The procedure should be captured in the narrative as part of the action taken in 
response to the illness. 
Progression of the Underlying Cancer  
Do not use the term ‘disease progression’ when reporting an AE because it is too gene ral. 
Instead, report the specific disease (clinical) manifest ation of the progression 
(e.g.,  ‘malignant pleural effusion’, ‘spinal bone metastases’, ‘lymphadenopathy from 
underlying non-Hodgkin l ymphoma’, ‘brain metastases’).  
Pregnancy  
Notification to Drug  Safety: Based on the estimated date of conception, complete a 
Pregnancy Report Form for all pregnancies that occur from the time of informed consent to the end of the protocol-defined contraception period, including any pregnancies that occur in the partner of a male study patient. Fax the form to the sponsor’s Drug Safety Department within 48 hours of becoming aware of the pregnancy. All pregnancies that occur during this time period will be monitored for the full duration; all perinatal and neonatal outc omes 
should be reported. Infants should be followed for a minimum of 8 weeks. 
Collection of data: Based on the estimated date of conception, a ll pregnancies that occur 
from time of informed consent to within 30 days of last study drug dose, including any 
pregnancies that occur in the partner of a male study patient, will also be recorded on the Adverse Events and Pre-Existing Conditions CRF. Abortion, whether accidental, therapeutic, or spontaneous, should be reported as an SAE. Congenital anomalies o r birth defects, as 
defined by the ‘serious’ criterion above (see definitions Section 7.6.1.1) should be reported as SAEs.  
7.6.1.3  Reporting Periods for Adverse Events and Serious Adverse Events 
The safety reporting period for all AEs and SAEs is from study Day 1 (predose) through the EOT visit or 30 days after the last study treatment (blinded study treatment or any component 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 39 of 68 of CHP), whichever is later. However,  all study protocol- related AEs are to be collected from 
the time of informed consent. All SAEs that occur after the safety reporting period and are 
considered study treatment-related in the opinion of the investigator should also be reported to the sponsor.  
SAEs will be followed until significant changes return to baseline, the event stabilizes (recovering/resolving) or is no longer considered clinically significant by the investigator, or the patient dies or withdraws consent. All non-serious AEs will be followed through the safety reporting period . Certain non-serious AEs of interest may be followed until resolution, 
return to baseline, or study closure. 
7.6.1.4  Serious Adverse Events Require Immediate Reporting  
Within 24 hours of observing or learning of an SAE, investigators are to report the event to 
the sponsor (or designee) , rega rdless of the relationship of the event to the study treatment 
regimen.  
For initial SAE reports, available case details are to be recorded on an SAE form. At a 
minimum, the following should be included: 
● Patient number 
● Date of  event onset  
● Description of the event 
● Study treatment, if known 
 
The completed SAE form and SAE Fax Cover Sheet are to be faxed to the sponsor ’s Drug 
Safety Department at (425) 527-4308 within 24 hours, unless otherwise instructed on the 
sponsor’s SAE form. 
Relevant follow-up information is to be submitted to the sponsor as soon as it becomes 
available.  
7.6.1.5  Sponsor Safety Reporting Requirements in the United States  
According to the final rule amending the IND safety  reporting requirements under  21 CFR 
312.32 and the FDA draft guidance Safety Reporting Requirements for INDs and BA/BE Studies (September 2010), endpoints that assess disease- related mortality or major morbidity 
as well other SAEs that are not study endpoints, but are known consequences of the underlying disease or condition that are anticipated to occur in the study population should not be reported to the FDA as individual IND safety reports. 
In this study, SAEs of disease progression do not require individual IND  safety reports.  
These anticipated SAEs will be reviewed periodically by an Independent Data Monitoring 
Committee and/or Seattle Genetics Drug Safety Department . If, upon review, an SAE is 
occurring at a higher rate than that which would be expe cted for the experimental arm, then 
an IND safety report for the SAE will be submitted to the FDA  by the sponsor. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 40 of 68 These safety reporting requirements apply  only to the process by which the sponsor reports 
SAEs to the FDA. Investigators are required to report all SAEs, including anticipated SAEs, 
to the sponsor. In addition, the sponsor will report all SAEs to international authorities as 
required per local reg ulatory reporting requirements. 
7.6.2  Clinical Laboratory Tests  
Samples will be drawn for central and local labs . Local laboratory testing will include 
institutional standard tests for evaluating safety and making clinical decisions . The following 
laboratory assessments will be performed by the central lab to evaluate safety at scheduled time points (see Appendix A ) during the course of the study: 
● The chemistry panel is to include the following tests: albumin, alkaline phosphatase, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen, calcium, creatinine, chloride, lactate dehydrogenase (LDH), phosphorus, potassium, sodium, total bilirubin, uric acid, and glucose. 
● The CBC with differential is to include the following tests: white blood cell count 
with five -part differential (neutrophils, lymphocytes, monocytes, eosinophils, and 
basophils), red blood cell count, platelet count, and hemoglobin/hematocrit. 
● Hgb A1c will be ob tained at baseline.  
The following laboratory assessment will be performed by local laboratories at scheduled time points (see Appendix A ) during the course of the stu dy: 
● A serum or urine β-hCG pregnancy test for fe males of childbearing potential 
7.6.3  ECOG Performance Status 
ECOG pe rformance status (see Appendix B ) will be evaluated at protocol- specified time 
points. 
7.6.4  TNSn  
The Total Neuropathy Score-nurse is a tool used in the assessment of neuropathy, including 
an examination conducted by a healthcare professional . A composite neuropathy score is 
calculated which includ es subjective sensory symptoms, subjective report of symptoms and 
amount of difficulty with daily activities, deep tendon reflexes, manual muscle testing, and 
pin sensibility . 
7.6.5  Monitoring of Patients with Hepatitis  
Carriers of chronic hepatitis C should be closely monitored for clinical and lab oratory signs 
of active infection during study treatment.  
7.7 Appropriateness of Measurements  
Internationally accepted criteria for the evaluation of lymphoma will be employed to assess 
tumor lesion size and extent of dise ase in the determination of PFS and response rate in this 
Study SGN35 -014  Clinical Protocol   Amend ment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 41 of 68 study ( Cheson 2007). The schedule for tumor imaging is consistent with general oncological 
practice and appropriately balances measurement of tumor control with the expense and 
patient inconvenience associated with CT and PET scanning. 
The safety measures that will be used in this trial are considered standard procedures for 
evaluatin g the potential adverse effects of study medications.  
The QLQ -C30 is a validated questionnaire developed by the EORTC to assess the quality of 
life of cancer patients  (Aaronson 1993). In this study, the neurotoxicity sub scale of the 
FACT/GOG-NTX questionnaire was selected as a measure to enable assessment of the effect 
of neurotoxicity on patients in the study. The EQ -5D is a validated instrument for use as a 
measure of health outcome. These PROs have been incorporated into previous clinical trials that seek to quantify the quality of life in patients . The TNSn is a tool tha t will allow precise 
measurement of the onset, resolution, and characterization of peripheral neuropathy. 
Immunogenicity is commonly assessed for biologics; therefore, standard tests will be 
performed to detect the possible presence of specific antibodies to brentuximab vedotin. Pharmacokinetic assessments for drug activity are also common in clinical studies.  
8 DATA QUALITY CONTROL  AND QUALITY ASSURAN CE 
8.1 Site Training and Monitoring Procedures  
A study manual with instructions for study compliance and CRF completion will be provided. Prior to the enrollment of patients at the site, Seattle Genetics or its designated clinical and medical personnel will review the following items with the investigator and clinic staff:  
● The protocol, study objectives, eligibility requirements, study procedures, registration and withdrawal processes 
● Current Investigator’s Brochure/ package insert 
● Reco rding and reporting AE and SAE 
● Enrollment goals and study timelines  
● The CRF completion process and source documentation requirements 
● Monitoring requirements 
● Institutional Review Board/Independent Ethics Committee (IRB/IEC) review and approval process 
● Informed consent process 
● GCP  guidelines and related regulatory documentation requirements 
● Key study team roles and responsibilities  
● Investigational product storage, accountability, labeling, dispensing and record keeping  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 42 of 68 ● Patient coding and randomization (if applicable) 
● Study samples/specimen collection, handling and shipping 
● Protocol compliance 
● Clinical study record keeping, document retention, and administrative requirements 
Monitoring visits will occur periodically, with frequency dependent on the rate of enrollment 
and workload at each site. During monitoring visits, the Seattle Genetics representative will review regulatory documentation, CRFs, source documentation, and investigational product storage, preparation, and accountability . The CRFs will be reviewed for completeness, 
adherence to the provided guidelines, and accuracy compared to the source documents. The investigators must ensure that the monitor is allowed to inspect all source documents pertinent to study patients, and must cooperate with the monitor to ensure that any problems noted in the course of the trial are resolved. The investigator must maintain a comprehensive and centralized filing system of all study -related documentation that is suitable for inspection 
by Seattle Genetics or its designated monitors and by quality assurance auditors, FDA representatives, or representatives of other regulatory agencies.  
8.2 Data Management Procedures  
Seattle Genetics will provide CRF Completion Guidelines for eCRF data entry . Study 
specific data management procedures will be maintained in the data management plan . 
Queries resulting from edit checks and/or data verification procedures will be  posted 
electronically in the eCRF . 
8.3 Access to Source Data 
The investigator will permit the sponsor’s representatives to monitor the study as frequently 
as the sponsor deems necessary to determine that protocol adherence and data recording are 
satisfactory . Appropriate measures to protect patient confidentiality are to be employed 
during monitoring. The CRFs and related source documents will be reviewed in detail by the monitor at each site visit. Original source documents or certified copies are needed for review . This review includes inspection of data acquired as a requirement for participation in 
this study and other medical records as required to confirm information contained in the CRFs, such as past history, secondary diagnoses, disease assessm ent records, adverse events, 
and concomitant medications. Other study records, such as correspondence with the sponsor and the IRB/IEC and screening and drug accountability logs will also be inspected. All source data and study records must also be available for inspection by representatives of the FDA  or other regulatory agencies.  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 43 of 68 8.4 Accuracy and Reliability of Data 
Steps to be taken to assure the accuracy an d reliability of data include: 
● The selection of qualified investigators and appropriate study centers. 
● Review of protocol procedures with the investigators and associated personnel prior 
to the study. 
● Periodic monitoring visits by the designated monitor(s).  
● CRFs will be reviewed for accuracy and completeness by the designated monitor(s) during monitoring visits to the study centers . Any discrepancies will be resolved with 
the investigator or designees as appropriate.  
8.5 Quality Assurance Procedures  
The Clinical Quality Assurance group or its designee may conduct audits at the clinical site 
or other study- related facilities and organizations . Audit reports will be retained by the 
Clinical Quality Assurance group of Seattle Genetics as part of the written record.  
8.6 Data Handling and Record Keeping 
8.6.1  Data Handling  
It is the investigator’s responsibility to ensure the accuracy, completeness, legibility, and 
timeliness of the data reported to the sponsor in the CRFs and in all required reports. Data 
reported on the CRF that is derived from source documents should be consistent with the source documents or the discrepancies should be explained. Any change or correction to a CRF will be maintained in an audit trail within the electronic data capture system.  
The investigator should retain records of the changes and corrections, written and/or 
electronic.  
Data hand ling procedures for this trial have been designed to permit data changes so that they 
are documented  by an audit trail. Data changes may only be made by those individuals so 
authorized. 
8.6.2  Investigator Record Retention 
The investigator shall retain study drug disposition records, copies of CRFs (or electronic 
files), and all source documentation (such as original ECG tracings, laboratory reports, 
inpatient or office patient records) for the maximum period required by the country and 
Institution in which the study will be conducted, or for the period specified by Seattle Genetics, whichever is longer . The investigator must contact Seattle Genetics prior to 
destroying any records associated with the study . If the investigator withdraws from the study 
(due to relocation, retirement, etc.), the records shall be transferred to a mutually agreed upon designee, such as another investigator  or IRB/IEC . Notice of such transfer will be provided in 
writing to Seattle Genetics.  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 44 of 68 9 DATA ANALYSIS METHOD S 
9.1 Determination of Sample Size 
Approximately 450 patients (~ 225 patients per treatment arm) will be randomized in this 
study. The  target proportion of patients with a diagnosis of sALCL per central pathology 
assessment will be 75% (+/ -5%), i.e., 338 (+/-23) patients . The sponsor wi ll monitor the 
proportion of sALCL and non- sALCL patients per central pathology assessment to ensure 
that the enrollment targets are reached and not exceeded.  
 
  
 
 
 
9.2 Study Endpoint Definitions  
9.2.1  Primary Endpoint : PFS per IRF  
Progression- free survival (PFS) is defined as the time from the date of randomization to the 
date of first documentation of PD, death due to any cause, or receipt of subsequent anticanc er 
chemotherapy to treat residual or progressive disease, whichever occurs first . Note that 
receipt of post treatment radiotherapy, post treatment chemotherapy for the purpose of 
mobilizing peripheral blood stem cells, or consolidative autologous or alloge neic SCT will 
not be considered as disease progression or as having started new anticancer therapy. Patients without documentation of PD/relapse, subsequent anticancer therapy for residual or progressive disease, or death at the time of analysis, will be c ensored at the date of last 
radiographic disease assessment . In the absence of a PFS event, patients receiving post 
treatment radiotherapy, post treatment chemotherapy for the purpose of mobilizing peripheral blood stem cells, or consolidative autologous or allogeneic SCT will be censored at the most recent tumor assessment before the data cutoff or study withdrawal, whichever occurs first.  
If PD is not documented, no subsequent anticancer chemotherapy to treat residual or progressive disease has been initiated, and the patient is alive at the time of the data cutoff or study withdrawal, PFS will be censored as follows: 
If there is no radiographic postbaseline tumor assessment, PFS will be censored at the date of 
randomization. 
If there are radiographic post baseline tumor assessments, PFS will be censored at the most 
recent tumor assessment before the data cutoff or study withdrawal, whichever occurs first.  

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 45 of 68 Detailed methodology , including handling rules for missing assessments and censoring 
approaches for the analysis of PFS,  is provided in the Statistical Analysis Plan ( SAP). 
9.2.2  Secondary Efficacy Endpoints  
9.2.2.1  PFS per IRF in Patients with sALCL  
PFS per IRF in patients with sALCL is defined in the same manner as the primary endpoint 
of PFS per IRF . For this endpoint, PFS per IRF will be analyzed in the sub set of patients with 
a central pathology  confirmed diagnosis of sALCL 
9.2.2.2  Complete Remission (CR) Rate  per IRF  
Complete remission  (CR) rate is defined as the proportion of patients with CR at the end of 
treatment  per IRF according to the Revised Response Criteria for Malignant Lymphoma 
(Cheson 2007). Patients whose disease response cannot be assessed wi ll be scored as non-
responders for calculating the CR rate.  
9.2.2.3  Overall Survival  
Overall survival (OS) is defined as the time from randomization to death due to any cause. Specifically,  
 OS = Date of death – Date of randomization + 1 
For a patient who is not known to have died by the end of study follow-up, observation of OS is censored on the date the patient was last known to be alive (i.e., date of last contact). Patients lacking data beyond the day of randomization will have their survival time censored on the date of randomization (i.e., OS duration of 1 day). 
9.2.2.4  Objective Response Rate per IRF  
ORR per IRF is defined as the proportion of patients with CR or partial remission ( PR) per 
IRF following the completion of study treatment (at EOT) according to the Re vised 
Response Criteria for Malignant Lymphoma ( Cheson 2007). Patients whose disease response 
cannot be assessed will be scored as non -responders for calculating the ORR. 
9.2.3  Additional Endpoints  
9.2.3.1  Incidence of ATA  
The ATA incidence rate is defined as the proportion of patients that develop ATA at any time 
during the study. 
9.2.3.2  Medical Resource Utilization  
Medical resource utilization data include medi cal care encounters (e.g., hospital admissions 
or major diagnostic procedures) related to study treatment or treatment for lymphoma . 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 46 of 68 9.2.3.3  Quality of Life  
Changes in quality of life will be measured based on PROs according to the QLQ-C30, 
FACT/GOG- NTX subscale, and EQ-5D. 
9.3 Statistical and Analytical Plans  
The statistical and analytical plans presented below summarize the more complete plans to be detailed in the statistical analysis plan (SAP) . A change to the data analysis methods 
described in the protocol will require a protocol amendment only if it alters a principal feature of the protocol. The SAP was finalized prior to first patient visit. Any changes to the 
methods described in the final SAP will be described and justified in the clinical study  report. 
9.3.1  Gene ral Considerations  
9.3.1.1  Randomization and Blinding 
This is a randomized, double-blind, placebo controlled comparative study that will enroll approximately 450 patients . Patients  will be randomized in a 1:1 manner to receive either 
CHOP or brentuximab vedotin plus CHP . Brentuximab vedotin or vincristine will be 
administered as a placebo -controlled double-dummy and provided to sites in a blinded 
manner.  
 
  
 
  
  
  
  
Randomizatio
n will be performed centrally using a system that will assign a unique patient 
randomization number but will not specify the actual treatment assignment. Randomization procedures are detailed in the Study Manual.  
9.3.1.2  Adjustments for Covariates  
This is a phase 3 study. Stratified analyses will include adjustment for the stratification factors  as recorded at randomization (described in Section 9.3.1.1). Covariates may be 
considered for adjustment in exploratory regression analyses. 
9.3.1.3  Handling of Dropouts and Missing Data  
Missing data will not be imputed, with the exception of AE start dates while calculating 
duration of events. Patients with missing values of a variable other than the time -to-event 
endpoints  (PFS and OS) will be excluded from the analysis of that endpoint. Censoring rules 
will be ap plied to the estimation of the distribution of the time -to-event endpoints  (see 
Sections 9.2.1 and 9.2.2.3).  

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 47 of 68 9.3.1.4  Multicenter Studies  
There are multiple centers in this study, however it is not anticipated that any center will 
accrue enough patients to warrant an analysis by center.  
 
 
 
 
 
 
 
 
 
 
 
 
9.3.1.6  Data Transformations and Derivations  
The date of progression will be the earliest of all radiologic scan dates for the given disease assessm ent. No other data transformation is planned for the primary or secondary efficacy 
endpoints. 
9.3.1.7  Analysis Sets  
Intent- to-Treat (ITT) Analysis Set : The ITT analysis set will include all randomized patients . 
Patients will be included in the treatment group assigned at randomization regardless of the 
actual treatment received.  
Safety Set : The safety analysis set will include all patients who receive any amount of 
brentuximab vedotin or any component of CHOP. Treatment group will be determined using the actual tre atment received, regardless of the randomization treatment assignment. Patients 
receiving any dose of brentuximab vedotin will be grouped into the experimental group. Patients who do not receive brentuximab vedotin but receive any dose of any component of CHOP will be grouped into the standard-of- care group. 
9.3.1.8  Examination of Subgroups  
As exploratory analyses, subgroup analyses may be conducted for selected endpoints. Detailed methodology will be provided in the SAP. 
 
 

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 48 of 68  
   
  
 
 
 
 
 
9.3.2  Patient  Di
sposition 
An accounting of study patients by disposition will be tabulated by treatment group . The  
number of patients in each analysis population will be summarized by treatment group. 
Patients who discontinue study treatment and patients who withdraw from the study will be summarized by treatment and reason for discontinuation or withdrawal and listed.  
9.3.3  Patient  Characteristics  
Demographics, other baseline characteristics, and concomitant medications will be summarized by treatment group and listed.  
9.3.4  Treatment Complian ce 
The dose administered at each cycle for each treatment agent will be assessed and dose intensity will be summarized . Details will be provided in the SAP.  
9.3.5  Efficacy Analyses  
9.3.5.1  Primary Efficacy Analyses 
Kaplan -Meier methods will be used to assess PFS . The stratified log -rank test without 
adjustments for covariates will be used in the primary evaluation of PFS differences between the experimental arm and the standard -of-care arm in the ITT analysis set using a one-sided, 
α = 0.025 level test . All events ente red in the database at the time of analysis that have been 
source data-verified will be included in the analysis of PFS, even if there are more than the prespecified number of events. 
Kaplan -Meier Curves depicting PFS in the 2 arms will be generated . Additionally, median 
PFS and probability of PFS from 3 months to the end of the follow-up period will be reported 
at 3-month intervals. The two -sided 95% confidence intervals (CI) for the median and 
3-month intervals will be calculated using the complementary log -log transformation method 
(Collett 1994). Detailed methodology is provided in the SAP. 
9.3.5.2  Secondary Efficacy Analyses 
ORR  and CR rate will be summarized by treatment group  using the ITT analysis set . An 
exact two -sided 95% confidence interval using the Clopper-Pearson method ( Clopper 1934) 
will be calculated.  

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 49 of 68 OS will be analyzed using Kaplan -Meier methodology and Kaplan- Meier plots will be 
provided by treatment group using the ITT analysis set . The median OS and its two -sided 
95% CI using the complementary log- log transformation meth od (Collett 1994 ) will be 
calculated by treatment group.  
9.3.6  Pharmacokinetic and Pharmacodynamic Analyses 
Antibody drug-conjugate (brentuximab vedotin) and unconjugated drug (MMAE) levels in 
serum or plasma will be summarized with descriptive statistics at each PK sampling time 
point. Any additional PK and PK/PD analyses may be described in a separate analysis  plan 
and presented in a separate report. 
9.3.7  Health Outcomes  Analyses 
EQ-5D scores and MRU  data will be summarized using descriptive statistics by treatment 
group. 
Quality of life total and subscale scores will be summarized with descriptive statistics by 
treatment group and visit using the ITT analysis set. In addition, change from baseline will be 
tabulated by treatment group and visit. Descriptive summaries of individual items may also be presented.  
Additional statistical modeling for MRU and PRO measures may be performed separately in 
post hoc analyses. 
9.3.8  Safety Analyses 
9.3.8.1  Extent of Exposure  
Duration of treatment, number of cycles, total dose and dose intensity will be summarized by 
treatment arm  using the safety  analysis set . Dose modifications will also be summarized.  
Details will be provided in the SAP. 
9.3.8.2  Adverse Events 
Adverse events will be defined as treatment emergent if they are newly occurring or worsen 
following treatment with brentuximab vedotin, cyclophosphamide, doxorubicin, vincristine, 
or prednisone. The incidence of all AEs, treatment -emergent AEs, and treatment -related AEs 
will be tabulated by treatment group using the safety  analysis set . AEs will be classified by 
system organ class and preferred term using the Medical Dictionary for Regulatory Activities 
(MedDRA).  
AEs will be listed and summarized by treatment group, MedDRA preferred term, severity, and relationship to study drug using the safety  analysis set . In the event of multiple 
occurrences of the same AE with the same preferred term in one patient, the AE will be 
counted once as the occurrence. The incidence of AEs will be tabulated by preferred term and treatment group. AEs leading to premature discontinuation of study drug or withdrawal from the study will be summarized and listed in the s ame manner.  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 50 of 68 9.3.8.3  Deaths and Serious Adverse Events 
Serious adverse events will be listed and summarized in the same manner as all AEs . 
Adverse events with a fatal outcome will be listed.  
9.3.8.4  Clinical Laboratory Results  
Summary statistics for actual values and for change from baseline will be tabulated as 
appropriate for laboratory results by treatment group and scheduled visit using the safety  
analysis set . Patients with laboratory values outside of the normal reference range at any 
postbaseline assessment will be listed by treatment group.  
9.3.9  Interim Analys is 
An Independent Data Monitoring Committee (IDMC) will periodically monitor the trial for safety  and will review expedited SAEs as they arise. 
 
 
 
The IDMC conduct of ongoing safety reviews  
will be documented in the IDMC Charter. 
10 INFORMED CONSENT, ETHICAL REVIEW, AND RE GULATORY 
CONSIDERATIONS  
10.1 Informed Consent  
The investigator is responsible for presenting the risks and benefits of study participation to the subject  in simple terms using the IRB/IEC approved informed consent document and for 
ensuring patients are re -consented when the informed consent document is updated during 
the study, if required. The investigator will ensure that written informed consent is obtained 
from each patient,  or legally authorized representative , if applicable,  by obtaining the 
signature and date on the informed consent document prior to the performance of protocol evaluations or procedures. 
If informed consent is obtained from a legally authorized representative for a patient  who is 
unable to provide informed consent at study entry, but the patient  is later able to provide 
informed consent, the investigator must obtain written informed consent from the patient.  
10.2 Ethical Review 
The investigator will provide the sponsor or its designee with documentation of the IRB/IEC 
approval of the protocol and the informed consent document before the study may begin at 
the investigative site(s) . The name and address of the reviewing ethics committee are 
provided in the investigator file. 
The investigator will supply the following to the investigative site’s IRB/IEC : 

Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 51 of 68 ● Protocol and amendments 
● Informed c onsent document and updates 
● Clinical Investigator’s Brochure and updates 
● Relevant curricula vitae, if required  
● Required safety and SAE reports 
● Any additional submissions required by the site’s IRB/IEC 
 
The investigator must provide the following documentation to the sponsor or its designee: 
● The IRB/IEC periodic (e.g. quarterly, annual) re-approval of the protocol. 
● The IRB/IEC approvals of any amendments to the protocol or revisions to the 
informed consent document. 
● The IRB/IEC receipt of safety and SAE repo rts, as appropriate. 
10.3 Regulatory Considerations  
This study will be conducted in accordance with the protocol and ethical principles stated in 
the applicable guidelines on good c linical practice, and all applicable federal, state, and local 
laws, rules, and regulations.  
All data recorded in the CRF  for patients participating in this study will be transcribed from 
medical records or other source documents. 
10.3.1  Investigator Information 
The contact information and qualifications of the principal investigator and subinvestigators 
and name and address of the research facilities are included in the investigator file.  
10.3.2  Protocol Amendments and Study Termination 
Any investigator- initiated changes to the protocol (with the exception of changes to eliminate 
an immediate ha zard to a study patient ) must be approved by the sponsor prior to seeking 
approval from the IRB/IEC, and prior to implementing. The investigator is responsible for enrolling patients  who have met protocol eligibility criteria . Protocol deviations must be 
reported to the sponsor and the local IRB/IEC in accordance with IRB/IEC policies.  
The sponsor may terminate the study at any time . The IRB/IEC must be advised in writing of 
study completion or early termination.  
10.4 Study Documentation, Privacy and Records Ret ention 
Government agency regulations and directives require that all study documentation pertaining to the conduct of a clinical trial must be retained by the investigator  until notified 
by the sponsor in writing that retention is no longer necessary. 
To protect the safety of participants in the study and to ensure accurate, complete, and 
reliable data, the investigator will keep records of laboratory tests, clinical notes, and patient  
medical records in the patient files as original source documents for th e study . If requested, 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 52 of 68 the investigator will provide the sponsor, its licensees and collaborators, applicable 
regulatory agencies,  and applicable IRB/IEC with direct access to original source documents 
or certified copies.  
Records containing patient medical information must be handled in accordance with the 
requirements of the Health Information Portability and Accountability Act (HIPAA ) Privacy 
Rule and consistent with the terms of the patient  authorization contained in the informed 
consent document for th e study (the Authorization). Care should be taken to ensure that such 
records are not shared with any person or for any purpose not contemplated by the Authorization. Furthermore, case report forms and other documents to be transferred to the sponsor should be completed in strict accordance with the instructions provided by the sponsor, including the instructions regarding the coding of patient  identities.  
In compliance with local and/or regional regulations, this trial may be registered and trial results m ay be posted on public registries, such as ClinicalTrials.gov. 
10.5 Clinical Trial Agreement  
Payments by the sponsor to investigators and institutions conducting the trial, requirements for investigators’ insurance, the publication policy for clinical trial data, and other requirements are specified in the clinical trial agreement.  
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 53 of 68 11 REFERENCES  
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, 
de Haes JC and et al. (1993). The European Organization for Research and Treatment of Cancer QLQ -C30: a 
quality -of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365 -76. 
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M and Diehl V (2007). Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579- 86. 
Clopper CJ and Pearson ES (1934). T he use of confidence or fiducial limits illustrated in the case of the 
binomial. Biometrika 26: 404 -413. 
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P and Gisselbrech t C (2002). CHOP chemotherapy plus rituximab compared with 
CHOP alone in elderly patients with diffuse large -B-cell lymphoma. N Engl J Med 346: 235- 42. 
Collett D (1994). Interval- censored survival data. Modelling survival data in medical research. Boca Rat on, 
Fla., Chapman & Hall/CRC: 237 -251. 
Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S and McMillan A (2011). Guidelines for the management of mature T -cell and NK -cell neoplasms (excluding cutaneous T -cell 
lymphoma). Br J Haemato l 153: 451- 85. 
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camos M, Colomo L, Espinosa I, Martinez S, Ribera JM, Martino R, Gutierrez- Garcia G, Montserrat E and Lopez- Guillermo A (2008). Intensive 
chemotherapy (high -dose CHOP/ESHAP regimen ) followed by autologous stem -cell transplantation in 
previously untreated patients with peripheral T -cell lymphoma. Ann Oncol 19: 958- 63. 
National Comprehensive Cancer Network (2013). NCCN Guidelines Version 1.2013: Non -Hodgkin's 
Lymphomas. Available at: http://www.nccn.org. Accessed February 21, 2013.  
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA and Shustov A (2012). Brentuximab vedotin (SGN -35) in patients w ith 
relapsed or refractory systemic anaplastic large cell lymphoma: Results of a phase II study. J Clin Oncol 30: 2190- 6. 
Savage KJ (2008). Prognosis and primary therapy in peripheral T -cell lymphomas. Hematology Am Soc 
Hematol Educ Program: 280- 8. 
Schmitz  N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A and 
Pfreundschuh M (2010). Treatment and prognosis of mature T -cell and NK -cell lymphoma: an analysis of 
patients with T -cell lymphoma treated in studies of the Germa n High -Grade Non -Hodgkin Lymphoma Study 
Group. Blood 116: 3418- 25. 
Shipp MA (1993). A predictive model for aggressive non -Hodgkin's lymphoma. The International Non -
Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987- 94. 
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T and Gressin R (2010). Upfront VIP -reinforced -ABVD (VIP -rABVD) is n ot superior to CHOP/21 in newly 
diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS -LTP95. Br J 
Haematol 151: 159- 66. 
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW (2008). Chapter 
11: Mature T - and NK -cell Neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissues. 
Lyon, France, International Agency for Research on Cancer: 269 -319. 
Vose J, Armitage J and Weisenburger D (2008). International peripheral T -cell and natural killer/T -cell 
lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124 -30. 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 54 of 68 Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL and Forero -Torres A (2010). 
Brentuximab vedotin (SGN -35) for relapsed CD30- positive lymphomas. N Engl J Med 363: 1812- 21. 
 
 
S t u dy  SGN35 -014   C l in i c a l  P ro t o co l    Am en dm en t  5 ;  12 -D e c em b e r -2018  
B r en t u x im ab  v edo t i n   S e a t t l e  G en e t i c s ,  In c .  -  C on f i d en t i a l   P ag e  55  o f  68  APPEND IX  A :  STUDY  SCHEDULE   
 B a s e l i n e /S c r e e n i n g  E n r o l lm e n t  C y c l e  1  C y c l e s  2+  C y c l e  4  o n l y  L a s t  p l a n n e d  
c y c l e  o f  t x  EOT   
v i s i t  L o n g -t e rm  F /U  
M o n t h s  a f t e r  f i r s t  d o s e  
9 1 2  1 5  1 8  2 1  2 4  > 2 4  
V i s i t  W i n d ow  D-2 8  t o  1  D-7  t o  1  D-7  t o  1  D 1  D 1± 1  D a y  1 5 -2 1  D a y  1 5 -2 1   3 0 -3 7  d a y s  
p o s t  l a s t  d o s e f  ± 1  w k  E v e r y  6  m o s   
± 1  w k  
S c r e e n i n g /  
B a s e l i n e  
A s s e s sm e n t s  I n f o rm e d  c o n s e n t  X  
E l i g i b i l i t y  d o c um e n t a t i o n  s u bm i t t e d  t o  s p o n s o r  p r i o r  t o  
 s t u d y  s t a r t ;  r a n d om i z a t i o n j             
I n c l u s i o n / e x c l u s i o n  X              
M e d i c a l  h i s t o r y  X              
CD 3 0 / h i s t o l o g y a X              
HTLV -1  s t a t u s  X              
H g b  A 1 c  X              
IP I  s c o r e  X              
E c h o c a r d i o g r am  o r  MUGA  s c a n  Xo              
H e i g h t  &  w e i g h t   X             
E l e c t r o c a r d i o g r am   X             
P r e g n a n c y  t e s t   X     X        
T r e a tm e n t  S t u d y  t r e a tm e n t  a dm i n i s t r a t i o n    X X           
ATA /PK /PD  S am p l e s  f o r  ATA /PK /PD     S e e  S e c t i o n  7 . 3         
R e s p o n s e  
A s s e s sm e n t  L ym p h om a  a s s e s sm e n t b   Xl X  X Xf Xg Xg Xg Xg Xg Xg Xg 
CT  ( c h e s t ,  n e c k ,  a b d om e n ,  p e l v i s )  X    X X Xf Xg Xg Xg Xg Xg Xg Xg 
PET c X    X X Xf        
B o n e  m a r r ow  b i o p s y  Xd    Xe Xe Xe , f         
S u r v i v a l  s t a t u s          Xh  Xh  Xh Xh 
S a f e t y  
A s s e s sm e n t s  ECOG  p e r f o rm a n c e  s t a t u s   X  X   X        
S e r um  c h em i s t r y   X X X   X        
CBC  w i t h  d i f f e r e n t i a l   X X X   X        
C o n  m e d s  &  AE s  C o l l e c t  a n y  r e l a t e d  t o  s t u d y  p r o t o c o l  
p r o c e d u r e s   C o l l e c t  f r om  D a y  1  ( p r e d o s e )  t h r o u g h  3 0  d a y s  p o s t  l a s t  d o s e  o r  t h r o u g h  EOT  
v i s i t ,  w h i c h e v e r  i s  l a t e r         
TNS n  a s s e s sm e n t     X Xm   X Xn Xn Xn Xn Xn Xn  
PRO /MRU  QLQ -C 3 0     X X   X Xi Xi Xi Xi Xi Xi Xi 
M e d i c a l  R e s o u r c e  U t i l i z a t i o n     X  X    X  X  X  X  X  X  X  X  ( 3 0  m o  p o s t  
f i r s t  d o s e  o n l y )  
FACT /GOG -NTX  s u b s c a l e     X X   X Xn Xn Xn Xn Xn Xn  
EQ -5D     X X   X Xp X Xp X Xp X Xk 
 
a L o c a l l y  a s s e s s ed  t o  en ab l e  en r o l lm en t  ( s e e  S e c t i on  7  1  1  f o r  d e f i n i t i on  o f  CD3 0 -p o s i t iv i ty ) ;  tum o r  sp e c im en  
m u s t  b e  su bm i t t ed  f o r  c en t r a l  p a th o l og y  r e v i ew  b e f o r e  r an d om i z a t i on  t o  con f i rm  h i s to l o g y  ( an d  ALK  s t a tu s ,  i f  
ap p l i c ab l e )  an d  CD3 0  ex p r e s s i on  
b Co n s i s t s  o f  th e  f o l l ow i n g :  ph y s i c a l  ex am i n a t i on ,  p a t i en t  m ed i c a l  h i s t o ry ,  i n c l u d i n g  a  t h o r ou g h  r ev i ew  o f  th e  
p a t i en t ’ s  cu r r en t  s i g n s  an d  sym p t om s ,  B  sym p t om s ,  an d  con com i t an t  m ed i c a t i on s  S e e  S e c t i on  72 
c A  com b i n ed  CT /PET  m ay  b e  o b t a i n ed  t o  s a t i s f y  th e  r equ i r em en t s  f o r  CT  an d  PET  s c an n i n g ,  a s  l on g  a s  a  
d i ag n o s t i c  qu a l i ty  CT  s c an  i s  o b t a i n ed ;  PET  s c an s  m ay  a l so  b e  o b t a i n ed  an y  t im e  du r i n g  th e  s tu dy  i f  c l i n i c a l l y  
i n d i c a t ed  
d Ob t a i n ed  w i th i n  6 0  d ay s  o f  f i r s t  d o s e  o f  s tu d y  t r e a tm en t  
e B on e  m a r r ow  b i o p sy  i s  r equ i r ed  t o  con f i rm  r e sp o n s e  i f  b on e  m a r r ow  i s  p o s i t i v e  a t  b a s e l i n e  an d  sh ou l d  b e  
o b t a i n ed  w i th i n  4  w e ek s  a f t e r  d o cum en t a t i on  o f  r e sp on s e ;  d o e s  n o t  n e ed  t o  b e  r ep e a t ed  o n c e  b on e  m a r r ow  i s  
n eg a t i v e  
f R e sp o n s e  a s s e s sm en t s  a t  EOT  r equ i r ed  i f  n o t  p e r f o rm ed  a t  l a s t  cy c l e  o f  t r e a tm en t  EOT  ev a l u a t i on s  sh ou l d  b e  
o b t a i n ed  b e f o r e  t h e  i n i t i a t i on  o f  n on -p r o t o co l  th e r apy  I f  EOT  ev a l u a t i on s  a r e  com p l e t ed  b e f o r e  3 0  d ay s  
f o l l ow i n g  th e  l a s t  s t u dy  t r e a tm en t ,  con du c t  a  p h on e  s c r e en  3 0 -3 7  d ay s  f o l l ow i n g  th e  p a t i en t ’ s  l a s t  s t u dy  
t r e a tm en t  t o  en su r e  th a t  n o  ch an g e s  i n  AE  p r o f i l e  h av e  o c cu r r ed  g A f t e r  2 4  m on th s  f o l l ow i n g  th e  f i r s t  d o s e  o f  s t u dy  d ru g ,  r equ i r ed  ev e ry  6  m on th s  Ob t a i n  u n t i l  p a t i en t  
ex p e r i en c e s  PD  p e r  i n v e s t i g a t o r  a s s e s sm en t ,  d e a t h ,  o r  an a l y s i s  o f  th e  p r im a ry  en d p o i n t ,  wh i ch ev e r  com e s  f i r s t  
h On c e  a  p a t i en t  ex p e r i en c e s  PD  p e r  i n v e s t i g a t o r  a s s e s sm en t ,  su rv i v a l  s t a tu s  i s  r equ i r ed  ev e ry  6  m on th s  u n t i l  
d e a t h  o r  s t u dy  c l o su r e ,  wh i ch ev e r  com e s  f i r s t  A f t e r  3 0  m on th s ,  t h e  w i n d ow  f o r  th e  a s s e s sm en t  i s  ±1  m on th   
Co l l e c t  i n f o rm a t i on  r eg a r d i n g  su b s equ en t  an t i c an c e r  th e r ap i e s  
i Co l l e c t  u n t i l  p a t i en t  ex p e r i en c e s  PD  p e r  i n v e s t i g a t o r  a s s e s sm en t  o r  3 0  m on th s  p o s t  f i r s t  d o s e  o f  s t u dy  t r e a tm en t ,  
wh i ch ev e r  com e s  f i r s t  
j R an d om i z a t i on  t o  o c cu r  a f t e r  e l i g i b i l i ty  i s  d e t e rm i n ed  an d  w i th i n  1  bu s i n e s s  d ay  o f  p l an n ed  f i r s t  d o s e  o f  s t u dy  
t r e a tm en t  
k Req u i r ed  ev e ry  6  m on th s  u n t i l  d e a th  o r  s t u d y  c l o su r e ,  wh i ch ev e r  com e s  f i r s t  
l W i th i n  ≤4 8  h ou r s  p r i o r  t o  s tu dy  t r e a tm en t  
m Ev e ry  o d d -n um b e r ed  cy c l e  on l y  
n On l y  f o r  p a t i en t s  w i th  t r e a tm en t -em e rg en t  p e r i ph e r a l  n eu r o p a th y ;  co l l e c t  u n t i l  p a t i en t  ex p e r i en c e s  PD  p e r  
i n v e s t i g a t o r ,  i n i t i a t e s  a  su b s eq u en t  an t i c an c e r  t h e r apy ,  o r  u n t i l  2 4  m on th s  p o s t  f i r s t  d o s e ,  wh i ch ev e r  com e s  f i r s t  
o M ay  b e  o b t a i n ed  u p  t o  6  m on th s  p r i o r  t o  f i r s t  d o s e  o f  s t u dy  t r e a tm en t  
p No t  r equ i r ed  i f  p a t i en t  h a s  ex p e r i en c ed  PD  p e r  i n v e s t i g a t o r  a s s e s sm en t  
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 56 of 68 APPENDIX B : ECOG  PERFORMANCE STATUS  
Score  Description  
0 Normal activity . Fully active, able to carry on all pre -disease performance without 
restriction.  
1 Symptoms, but ambulatory . Restricted in physically strenuous activity,  but 
ambulatory and able to carry out work of a light or sedentary nature (e.g., light 
housework, office work). 
2 In bed <50% of the time . Ambulatory and capable of all self -care, but unable to carry 
out any work activities . Up and about more than 50% of waking hours. 
3 In bed >50% of the time . Capable of only limited self -care, confined to bed or chair 
more than 50% of waking hours. 
4 100% bedridden . Completely disabled . Cannot carry on any self -care. Totally 
confined to bed or chair. 
5 Dead.  
 
 
S t u dy  SGN35 -014   C l in i c a l  P ro t o co l     Am en dm en t  5 ;  12 -D e c em b e r -2018  
B r en t u x im ab  v edo t i n   S e a t t l e  G en e t i c s ,  In c .  -  C on f i d en t i a l   P ag e  57  o f  68  APPEND IX  C :  INTERNAT IONAL  PROGNO ST IC  INDEX  FOR  NHL  
Sco re  
 S co r e  
R i sk  F a c t o r  0  po i n t  1  po i n t  
Ag e  ≤60  y e a r s  >60  y e a r s  
S e rum  LDH  ≤1  x  ULN  >1  x  ULN  
ECOG  P e r f o rm an c e  S t a tu s  0  o r  1  2 ,  3, o r  4  
S t ag e  I  o r  I I  I I I  o r  IV  
Ex t r an od a l  Inv o l v em en t  ≤1  s i t e  >1  s i t e  
LDH  =  l a c t a t e  d e hy d r og e n a s e  
ECOG  =  E a s t e r n  C oop e r a t iv e  O n c o log y  G r oup  
ULN  =  upp e r  l im i t  o f  no rm a l  
R isk  Ca tego ry  
● L ow :        0 – 1  
● L ow -in t e rm e d i a t e :    2  
● H ig h -in t e rm e d i a t e :    3  
● H ig h :        4 – 5  
 
Ba s e d  o n  T h e  I n t e r n a t io n a l  N o n - H o dg k in ’ s  L ymph om a  P r o g n o s t i c  F a c to r s  P r o j e c t   
(Sh ip p  1 9 9 3 )  
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 58 of 68 APPENDIX D: INVESTIGATOR SIGNATU RE PAGE  
 
Investigator Statement and Signature  
I have read the attached protocol entitled “A randomized, double -blind, placebo -controlled, phase 3 study of 
brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30 -positive 
mature T -cell lymphomas” . 
I understand and agree to the provisions of the protocol, and I accept the responsibilities listed above in my role 
as principal investigator for the study.  
   
   
Investigator Signature   Date  
   
   
   
Investigator Name, Printed    
 
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 59 of 68 APPENDIX E: DOCUMENT HISTORY  
Version  Date  
Original  28-Jun-2012  
Amendment 1  27-Sep-2012  
Amendment 2  31-Jan-2013  
Amendment 3  05-Mar-2015  
Amendment 4  15-May-2018  
Amendment 5  12-Dec-2018  
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 62 of 68 Section(s)  Change  Rationale  
Schedule of 
Events  EQ-5D assessments at months 9, 15, and 21 of long -term follow up are not required 
if patient has experience progressive disease per investigator assessment  Clarification  
 
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 63 of 68 Summary of Changes in Amendment 2 
Section(s)  Change  Rationale  
Title Page  Added study name, ECHELON -2 Study has been given the name ECHELON -2 
Synopsis, 2.2 Changed secondary objective to refer to  remission rates rather than CR:  
To compare the complete  remission (CR) rate  rates  per IRF following the 
completion of study treatment between the 2 treatment arms  To pre -specify the analysis of both the complete 
remission rate and objective response rate per IRF  
Synopsis, 4.1 Added the following additional baseline laboratory inclusion criteria:  
● absolute neutrophil count (ANC) ≥1000/µL (unless documented bone marrow 
involvement with lymphoma ) 
● platelet count ≥50,000/µL (unless documented bone marrow involvement with 
lymphoma ) Additional safety precaution  to address a 
doxorubicin contraindication for myelosuppression 
Synopsis, 4.1 Female contraception period increased from 30 days to  at least 6 months  follow ing 
the last dose of study drug  Additional safety precaution  
Synopsis, 4.2 Excluded patients with the demyelinating form of Charcot -Marie -Tooth syndrome  Additional safety precaution to address a 
vincristine contraindication  
Synopsis, 4.2 Excluded patients who have had previous treatment with complete cumulative doses 
of doxorubicin or other anthracyclines  Additional safety pre caution to address a 
doxorubicin contraindication  
Synopsis, 4.2 Excluded p atients with known urinary outflow obstruction  Additional safety precaution to address a 
cyclophosphamide contraindication 
Synopsis, 2.4.2  Added new secondary endpoint:  
Objective response rate (ORR) per IRF following the completion of study treatment  Additional secondary endpoint  related to the 
modified secondary objective  
Synopsis, 9.3.1.9  Added estimated duration of study through final primary analysis and through final 
analysis  of OS  To provide greater clarity regarding the estimated 
duration of the study 
1.2, 11 Updated NCCN non -Hodgkin lymphoma guidelines to version 1.2013  To reference current NCCN guideline document  
5.2.9  Brentuximab vedotin should be reconstituted with the  appropriate amount of Sterile 
Water for Injection, United States Pharmacopeia (USP), or equivalent standard.  To allow for equivalent standards of sterile water 
for injection in regions outside the United States  
5.4.2  Specified that in Japan, cyclophospha mide and doxorubicin will be supplied by the 
study site and prednisone will be supplied by the sponsor  Clarification  
5.6.3  Specified that concomitant therapies should be excluded in accordance with 
approved prescribing information for each agent  Additional safety precaution  
 
Study SGN 35-014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 64 of 68 Section(s)  Change  Rationale  
7.1.1  Submission of the tumor block or approximately 15  unstained slides from a 
diagnostic biopsy is required prior to randomization  for subsequent central 
confirmation of CD30 expression, disease subtype, and ALK status for patients with 
a diagnosis of sALCL . The diagnostic specimen must be from a malignant lymph 
node or extranodal tissue  obtained by core or excisional/incisional biopsy . 
Cutaneous samples alone are unacceptable. Fine needle aspirate and cytology 
samples are also unacceptable.  Clarification  
7.3 Specified that b lood samples for PK testing will be collected at selected time  points  
in Cycle s 1 and 2  and at p redose in subsequent cycles  Clarification  
7.3 ATA to brentuximab vedotin will be measured predose at Cycles  1 through 4 and at 
EOT.  Clarification  
7.6.1.3  SAEs will be followed until significant changes return to baseline, the event 
stabilizes (recovering/resolving) or is no longer considered clinically significant by 
the investigator, or the patient dies or wi thdraws consent , or study closure . Additional safety precaution  
9.2.1  If death or PD occurs after 2 or more consecutively missed radiographic tumor 
assessments, censoring will be as above, where the most recent tumor assessment is 
the last radiologic tumor assessment p rior to the missed assessments.  
Detailed methodology  is, including handling rules for missing assessments and 
censoring approaches for the analysis of PFS,  is provided in the Statistical Analysis 
Plan (SAP) . Details of differing censoring  approaches are also presented in the 
SAP.  Handling rules for missed events and censoring 
approaches  will be provided in the SAP  
9.2.2.4  Added definition of ORR per IRF endpoint  To characterize the new secondary endpoint  
9.3 Specif ied that t he SAP was finaliz ed prior to first patient visit  Clarification  
9.3.1.5  Added the key secondary endpoint, ORR per IRF, to the analysis plan in fourth 
position after PFS per IRF in patients with sALCL, CR rate per IRF, and OS  Addition of ORR per IRF to analysis p lan 
9.3.5.2  Complete response  ORR and CR rate will be summarized by treatment group  using 
the ITT analysis set . An exact two -sided 95% confidence interval using the 
Clopper -Pearson method (Clopper 1934 ) will be calculated.  Clarification that ORR will also be  summarized  in 
the secondary efficacy analyses  
Schedule of 
Events  Specified that t he TNSn assessment will also be performed during odd -numbe red 
cycles from cycle 2 onwards  Clarification  
Schedule of 
Events  Removed footnote ‘d’ from Cycle 2 (Day 1 ±1) that  specified “ Obtained within 60 
days of first dose of study treatment ” Correction  
 
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 66 of 68 Section(s)  Change  Rationale  
9.2.1  If there is no radiographic postbaseline tumor assessment, PFS will be censored at  
Study Day 1  the date of randomization . Clarification  
Schedule of 
Events  Removed footnote that indicated that QLQ -C30 should only be collected at EOT if 
patient has not experienced disease progression  Correction  
 
Study SGN35 -014  Clinical Protocol   Amendment 5 ; 12-December -2018  
Brentuximab vedotin   Seattle Genetics, Inc. - Confidential  Page 68 of 68 Summary of Changes in Amendment 5 
Section(s)  Change  Rationale  
Synopsis   
The IDMC will provide 
recommendations to the sponsor 's Steering Committee as to appropriate study 
direction.  Correction. Recommendations were  to be  provided 
to the sponsor, not the sponsor’s Steering 
Committee.  
6.5 Reorganized section for clar ity. Specified that patients who have not progressed by 
the time of the primary analysis should get scanned per standard of care. Corrected 
inconsistencies with Ap pendix A.  Clarify assessments for the long -term follow up 
period, including assessments for patients who 
have not progressed by the time of the primary 
analysis  
6.5 and 
Appendix A  Changed the window for survival assessments to ± 1 month after 30 months from 
first dose  To prov ide additional flexibility  
 
